Search this site

Who are the ‘Bending Spoons’ of European HealthTech and MedTech? Executive Summary: Platform Consolidators The European healthcare technology landscape is currently navigating a period of profound structural transformation. Historically characterised by extreme fragmentation, a patchwork of national regulations, localised reimbursement models and legacy on-premise software, the sector has become the primary target for a new breed of operator: the "Platform Consolidator." Bending Spoons, an Italian technology company, has become the archetype for this model in the consumer app space, acquiring assets like Evernote and Vimeo to integrate them into a singular, highly efficient operating machine. This report suggests that while no single "clone" of Bending Spoons exists in European HealthTech, the philosophy has been adopted and adapted by three distinct archetypes: Sovereign Consolidators (infrastructure giants like CompuGroup Medical and Dedalus), Private Equity Platforms (financial aggregators like The Access Group, Main Capital, and Lanas Healthcare), and Venture Builders (consumer-health studios like Palta and HealthHero). 1. The Bending Spoons Paradigm: Defining the Operational Archetype To identify the "Bending Spoons" of European HealthTech, one must first establish a precise definition of the Bending Spoons archetype. It is insufficient to merely look for companies that acquire other companies; the "Bending Spoons" model is a specific, sophisticated operational strategy that differentiates itself from traditional holding companies or conglomerates. 1.1 The Four Pillars of the Model Based on the analysis of Bending Spoons' trajectory, from a bootstrap startup to a powerhouse acquiring assets like Evernote, Meetup, and Vimeo, four distinct operational pillars emerge. These pillars serve as the rubric against which European HealthTech players will be measured throughout this report. 1.1.1 Programmatic and Disciplined M&A Bending Spoons does not engage in M&A opportunistically; it is programmatic. The company targets assets that have "proven product-market fit" but are "financially inefficient" or "stagnating". They avoid venture-scale risks, preferring "steady compounding" over "Blitzscaling". The acquisition criteria are rigorous, often focusing on distressed or undervalued assets where they can pay "fair prices" (typically 3-5x adjusted EBITDA) rather than inflated tech multiples. 1.1.2 The Centralised "Operating System" Unlike a traditional holding company (eg. Berkshire Hathaway) that allows subsidiaries to operate autonomously, Bending Spoons integrates acquisitions into a centralised "platform." They have developed over 50 proprietary technologies, from A/B testing infrastructure to payment management systems, that are deployed across every portfolio company. This creates massive economies of scale; a new app does not need to build its own monetisation engine or SEO strategy, it simply plugs into the Bending Spoons "mainframe." 1.1.3 Radical Operational Efficiency (Operational Alpha) The hallmark of the Bending Spoons model is the aggressive rationalisation of costs to drive "Operational Alpha." This involves "right-sizing" workforces and centralizing functions like product, payments and legal.They often run lean teams, managing $100M+ businesses with teams of just 40 people, to maximise individual impact and speed. This focus on EBITDA margin expansion (often leveraging up to 5x EBITDA) allows them to service the debt used for acquisitions and recycle cash flow into the next deal. 1.1.4 Human Capital Arbitrage Bending Spoons employs a unique talent strategy: hiring "exclusively new graduates" and investing heavily in their development rather than hiring expensive, experienced executives. They view geographic strategy and talent density as core competitive advantages, treating talent allocation as a dynamic resource that can be moved rapidly to the highest-impact opportunities. 1.2 Translating the Model to Healthcare Applying this consumer-tech model to the regulated world of European healthcare requires adaptation. Regulatory Friction: You cannot "move fast and break things" when managing Electronic Patient Records (EPRs). Clinical safety governance prevents the rapid "sunset" of legacy features that Bending Spoons might execute in a note-taking app. Customer Lock-in: In consumer apps, users churn if they dislike a price increase. In healthcare, hospitals and clinics face massive switching costs. This makes the "recurring revenue" even stickier, justifying the "Buy and Hold" strategy even more than in consumer tech. Fragmentation: Europe is not one market; it is 30+ markets. A "Bending Spoons" in HealthTech must navigate the complexity of German DiGA reimbursement, French Ségur de la Santé funding, and UK NHS frameworks. Therefore, the "Bending Spoons" of HealthTech appear in different guises: The Infrastructure Roll-Up: Buying the operating systems of doctors and hospitals (CompuGroup, Dedalus). The PE Platform: Using private equity capital to roll up niche verticals like social care or dentistry (Access Group, Lanas). The Consumer Health Studio: Building apps on a shared data brain (Palta, HealthHero). 2. The Macro-Context: Why Europe? Why Now? The emergence of these consolidators is not accidental; it is driven by specific macroeconomic and structural factors in the European market. 2.1 The Valuation Arbitrage Opportunity Private Equity funds execute a "strategic arbitrage" in Europe. They acquire European HealthTech assets at lower entry multiples compared to the US, standardise operations to increase EBITDA and then sell them to global strategic buyers or list them at higher multiples. The "Mid-Tier" Gap: There is a "forgotten mid-tier" of European companies earning $5M to $10M EBITDA. These are too small for global strategics but perfect for PE-backed roll-ups. Multiple Expansion: By rolling up these small players into a larger platform, the valuation multiple expands from ~8-10x EBITDA (for small assets) to ~13x+ (for the consolidated platform). 2.2 The Fragmentation "Feature" Europe’s "patchwork" of regulatory environments is often seen as a bug, but for consolidators, it is a feature. Barriers to Entry: The complexity of complying with the German Digital Healthcare Act (DVG) or the French MaSanté 2022 strategy protects incumbents. Once a consolidator owns the certified software in a region, they have a defensible moat. Inorganic Growth Necessity: Because organic growth across borders is so difficult (due to local regulations), the only way to scale across Europe is through M&A. This forces the "Bending Spoons" model of acquiring local leaders rather than building from scratch. 2.3 The Shift to Private Equity The data indicates a massive shift of HealthTech assets from public markets to private ownership. Public markets often penalise the debt and integration costs associated with aggressive roll-ups. Private Equity, however, thrives on it. Delistings: Major players like CompuGroup Medical (via CVC) and Idox (via Long Path) are moving private to execute their strategies away from quarterly earnings pressure. Dry Powder: With early-stage VC funding plummeting, late-stage PE and "Buy and Build" strategies have become the primary liquidity pathway for founders. 3. The Sovereign Consolidators: The Infrastructure Architects These companies are the industrial-scale equivalents of Bending Spoons. They operate the mission-critical infrastructure, the digital "rails" of European healthcare. 3.1 CompuGroup Medical (CGM): The "Doctor's Desktop" Monopolist CompuGroup Medical (CGM) stands as the preeminent example of vertical market consolidation in the DACH region and beyond. Headquartered in Germany, CGM has spent decades executing a strategy that mirrors the Bending Spoons focus on recurring revenue and market dominance, albeit in the B2B sector. 3.1.1 The Consolidation of Ambulatory Care CGM’s primary thesis is the domination of the Ambulatory Information System (AIS) market, the software used by General Practitioners (GPs) and specialists to run their practices. Market Share as a Moat: In Germany, CGM’s market share in the AIS sector is formidable. By acquiring dozens of small, local software competitors over the years, they have created a scenario where switching costs for doctors are prohibitively high. US Expansion: Mirroring the global ambition of tech consolidators, CGM executed a major move into the US market with the acquisition of eMDs in 2020. This deal, along with the acquisitions of Schuyler House (lab software) and Medicus LIS, demonstrates a strategy of vertical integration. They are not just buying more GP software; they are buying the adjacent workflows (diagnostics, labs) to capture more of the value chain. 3.1.2 The Pivot to Data: "New Line" and "Insight Health" A critical evolution in the Bending Spoons model is the monetisation of the platform's data. CGM is actively executing this pivot. The Data Brokerage Strategy: The acquisition of a 20% stake in New Line (an Italian market analysis firm for pharmacy consumption data) and the acquisition of INSIGHT Health reveal the endgame. CGM is transitioning from a pure software vendor to a data platform. By aggregating anonymised prescription and diagnosis data from its thousands of AIS and PIS (Pharmacy Information Systems) installations, CGM creates a high-margin data product to sell to pharmaceutical companies and payers. This creates a "double monetisation" engine: the doctor pays for the software, and the industry pays for the data the doctor generates. 3.1.3 The Strategic Delisting with CVC Capital Partners In 2025, the trajectory of CGM shifted significantly. CVC Capital Partners, a leading global private markets manager, executed a strategic investment and subsequent delisting offer for CGM. The Rationale: Public markets demand quarterly growth. The Bending Spoons model—which often involves sacrificing short-term revenue to restructure costs or migrate tech stacks—is better executed in private. The partnership with CVC (who holds approx. 28% while the Gotthardt family retains control) provides the "patient capital" required for this transformation. Capital for M&A: CVC brings extensive experience in "platform" buyouts (e.g., Douglas, DKV Mobility). Their involvement signals a likely acceleration of M&A activity, potentially targeting larger, more complex assets that CGM could not have swallowed alone as a public entity. 3.2 Dedalus Group: The Pan-European Hospital Titan If CGM owns the doctor's office, Dedalus Group owns the hospital. Based in Italy, the home of Bending Spoons, Dedalus has grown into a top-tier European player through a series of "mega-mergers" orchestrated by its private equity owners. 3.2.1 The "Agfa" Transformation The defining moment for Dedalus was the acquisition of Agfa-Gevaert’s healthcare IT business for nearly €1 billion.This acquisition is analogous to Bending Spoons acquiring Evernote or Vimeo, buying a massive, established incumbent to achieve instant scale. Scale: The deal gave Dedalus a dominant position in the "DACH" region (Germany, Austria, Switzerland), France, and Brazil, instantly making it one of the largest Health IT companies in the world. The "D4P" Platform: Dedalus is working to consolidate its fragmented portfolio of acquired legacy systems (like ORBIS, Hydra, etc.) into a unified platform strategy known as "Dedalus 4 Patient" (D4P). This aligns with the Bending Spoons focus on centralisation, although the pace in hospital IT is necessarily slower than in consumer apps. 3.2.2 The Capital Engine: Ardian and ADIA The "Bending Spoons" model requires capital. Dedalus has access to some of the deepest pockets in the world. Ardian: The French private investment house Ardian holds a majority stake (approx. 92% indirectly) and has supported Dedalus since 2016. Their "buy-and-build" expertise has been the primary driver of Dedalus's expansion. ADIA: In 2021, the Abu Dhabi Investment Authority (ADIA) acquired a significant minority stake. This influx of sovereign wealth capital provides the "dry powder" needed to continue the consolidation of the European market, potentially targeting remaining independent players or competitors. Management Shift: The appointment of Alberto Calcagno (former CEO of Fastweb) and Andrea Fiumicelli signals a shift in corporate DNA. Moving from a founder-led software company to a management team with backgrounds in telecoms and large-scale infrastructure suggests a focus on operational efficiency, standardisation, and margin improvement—key tenets of the Bending Spoons philosophy. 3.3 Tietoevry Care: The Nordic Rationaliser Tietoevry represents the consolidation of the Nordic IT services market, formed by the merger of the Finnish Tieto and the Norwegian EVRY. 3.3.1 The "Demerger" Value Play Tietoevry is currently executing a strategic separation of its businesses. By spinning off or selling its "Tech Services" (consulting/infrastructure) division, it aims to focus on its high-margin software product units: Tietoevry Care, Tietoevry Banking and Tietoevry Industry. Focus on IP: This move is critical. The Bending Spoons model is predicated on high-margin Intellectual Property (IP), not low-margin services. By shedding the consulting arm, Tietoevry Care becomes a pure-play software consolidator in the health and social care space. Acquisition of MentorMate: To support this software focus, Tietoevry acquired MentorMate, a digital engineering firm with 1,000+ employees. This acquisition provides the engineering "muscle" needed to modernise the legacy health platforms they own, a strategy comparable to Bending Spoons' aggressive hiring of top engineering talent to refactor acquired codebases. 4. The Private Equity Algorithms: The Financial Bending Spoons While the companies above have their own brands, there is a class of "Platform Vehicles" created and managed entirely by Private Equity firms. These entities are arguably the purest implementation of the Bending Spoons model: they are financial algorithms designed to roll up software assets, extract synergies, and compound value. 4.1 The Access Group: The "Everything App" for UK Business The Access Group is a titan of the UK software market, valued at £9.2 billion and backed by Hg, TA Associates, and GIC. While it serves multiple verticals (HR, Hospitality, Legal), its Health, Support and Care (HSC) division is a massive, self-contained consolidator. 4.1.1 The Relentless M&A Machine Access Group’s acquisition pace is staggering, completing 20 acquisitions in a single year. In the health and care sector, their strategy is to buy every component of the "Integrated Care System" (ICS). Servelec: The £223.9M acquisition of Servelec was the keystone deal. Servelec provides the EPRs for community health and mental health trusts, as well as the case management software for social care. This connected Access to the NHS backbone. Adam HTT: Acquired to control the commissioning and procurement of care, Access now owns the software that local governments use to buy services from care providers. Alcuris & Oysta: These acquisitions moved Access into the "Technology Enabled Care" (TEC) market, smart alarms, fall detectors and remote monitoring. This moves the platform from purely administrative software to clinical and patient safety monitoring. Vincere & FastTrack: Acquisitions in the recruitment space allow Access to offer staffing solutions to the very care agencies that use their rostering software. 4.1.2 The "Access Workspace" Integration Layer The genius of Access Group and its strongest link to Bending Spoons, is Access Workspace. The Single Pane of Glass: Access does not let acquired companies rot in silos. They force integration into "Access Workspace," a unified single-sign-on (SSO) platform with a shared UI/UX. Cross-Selling as a Science: Once a customer is on Workspace, cross-selling is frictionless. A care home using Access for payroll sees the "Access Medication Management" module right on their dashboard. This drives the "Net Revenue Retention" (NRR) metrics that PE investors crave. Centralised "Success": Access centralises functions like "Employee Success" and "Customer Success", stripping these costs out of the acquired entities to improve EBITDA margins immediately post-acquisition. 4.2 Main Capital Partners: The "Performance Excellence" Architects Main Capital Partners is a specialised software investor focused on the Benelux, DACH, and Nordics. They are not just investors; they are operators. Their approach to "building software groups" is practically scientific. 4.2.1 The "Charly" Buy-and-Build Strategy Main Capital identifies a "platform" asset and then systematically acquires competitors to bolt onto it. SDB Groep (Benelux): Main acquired SDB (HR/Payroll for healthcare) and transformed it into a full-suite provider for the social care market. They bolted on childcare software, disability care planning tools, and e-learning modules, creating a comprehensive suite that no standalone competitor could match. Oiva Health (Nordics): Formerly VideoVisit, Main rebranded the company to Oiva Health and used it to consolidate the "virtual care" market in Finland and Denmark. This created a dominant player in remote patient monitoring and digital social care. Enovation: Another Main platform focused on secure healthcare communication. 4.2.2 Operational Alpha: The "Main" Playbook Main Capital’s differentiator is its "Performance Excellence" team. Standardisation: They have a standardised playbook for everything: from how to price SaaS contracts to how to structure international sales teams. Community: They organize "Main Software 50" awards and CTO days to share best practices across the portfolio. This ecosystem approach ensures that lessons learned in one company (eg, SDB) are instantly transmitted to another (e.g., Oiva), mimicking the "Palta Brain" or Bending Spoons' "shared knowledge" advantage. Continuation Funds: To avoid the pressure to sell good assets too early, Main recently raised a €520 million continuation fund. This allows them to hold high-performing assets like SDB and Björn Lundén for longer, compounding value over a decade rather than a traditional 3-5 year PE cycle. This aligns perfectly with the "permanent capital" mindset often associated with successful consolidators like Constellation Software. 4.3 Lanas Healthcare (Clanwilliam Group): The New Challenger In late 2025, a new "Bending Spoons" contender officially entered the arena: Lanas Healthcare. 4.3.1 The Origin Story Lanas was formed through the acquisition of Clanwilliam Group by TA Associates. Clanwilliam was already a significant consolidator, having spent 25 years rolling up pharmacy and practice management software across the UK, Ireland, and ANZ. 4.3.2 The "Platform" Rebirth TA Associates (who also back The Access Group) saw the potential to supercharge this model. Rebranding & Recapitalisation: They rebranded the group to "Lanas Healthcare Technology" to signal a new era and injected over $115 Million in committed M&A funding. The Mission: Founder Howard Beggs explicitly stated the goal is to "triple the size of the business" through organic growth and targeted acquisitions. Vertical Focus: Lanas is structured around core verticals: Pharmacy, Primary/Community Care, and Specialists. By focusing on these specific niches, they can acquire "best-of-breed" point solutions and integrate them into a broader suite, creating a "platform of platforms." The TA Playbook: The involvement of TA Associates suggests that Lanas will likely follow the Access Group playbook: aggressive M&A, rapid integration, and a focus on recurring revenue metrics. 5. The Consumer & Telehealth Platforms: The "App Store" Aggregators These companies operate in the consumer-facing (B2C) or B2B2C space. They are fighting for the "Digital Front Door", the app on the patient's phone. Their model mimics Bending Spoons' consumer app strategy but is applied to clinical services. 5.1 HealthHero: The "Asset-Light" Clinical Consolidator HealthHero, founded by Ranjan Singh, is built on the thesis that digital healthcare needs to be consolidated to be efficient. 5.1.1 The Regional Roll-Up HealthHero’s strategy acknowledges that healthcare is local. You cannot simply launch one app for all of Europe. Instead, they acquire the local champion in each market and integrate them on the backend. UK: Acquired Doctorlink (a leading digital triage and symptom checker). This gave them the "front door" technology used by millions of NHS patients. France: Acquired Qare (a leading video consultation provider). Germany: Acquired Fernarzt. Ireland: Acquired MyClinic. 5.1.2 The "Chronos" Platform HealthHero is not just a holding company. They are deploying a GenAI-powered platform called Chronos. Integration: Chronos is designed to be the "connective tissue" between these acquisitions. It unifies the clinical pathways, allowing a patient who enters via the Doctorlink triage engine to be seamlessly routed to a Qare doctor or a Fernarzt prescription service. Efficiency: By using AI for triage and pre-consultation data gathering, HealthHero aims to reduce the cost of clinical delivery, a classic Bending Spoons efficiency play. 5.2 Palta: The Co-Founding Studio Palta is the closest entity to Bending Spoons in terms of corporate culture and product focus (mobile-first consumer apps). 5.2.1 The "Palta Brain" Advantage Palta operates as a "co-founding" studio. They identify high potential niches and build or accelerate companies to dominate them. Portfolio: Their portfolio includes Flo (the #1 global period tracker with >200M users and >$100M ARR), Simple (intermittent fasting), and Zing (AI fitness). Shared Infrastructure: The "Palta Brain" platform is their version of Bending Spoons' proprietary tech stack. It provides centralised services for: User Acquisition (UA): Sharing data on ad performance across apps. Predictive Analytics: Using data from Flo to predict churn in Simple. Monetisation: Standardizing subscription models and pricing experiments. Operational VC: Unlike a standard VC that writes a check and attends board meetings, Palta provides the "operating system" for growth. This allows their portfolio companies to scale much faster and with leaner teams than standalone startups. 5.3 Redcare Pharmacy: The "Beyond-Pill" Ecosystem Redcare Pharmacy (formerly Shop Apotheke Europe) is a publicly traded company executing a massive pivot through M&A. 5.3.1 From Retailer to Platform Redcare realized that selling boxes of pills is a low-margin, commoditized business. The real value lies in "Medication Management." SmartPatient (MyTherapy): Redcare acquired the developers of MyTherapy, one of the world's leading medication adherence apps. This app is used by millions of chronic patients to track their meds. MedApp: A similar acquisition in the Netherlands to capture the adherence market there. First A: An acquisition in the "Quick Commerce" space to enable 30-minute delivery. 5.3.2 The Strategic Logic By owning the app that reminds the patient to take their pill (MyTherapy), Redcare owns the moment of consumption. They can then seamlessly prompt the patient to refill the prescription via Redcare Pharmacy. This creates a "closed loop" ecosystem that increases Customer Lifetime Value (CLV) and retention, moving the business model closer to a recurring revenue tech platform and further away from a traditional retailer. 6. The Vertical Market HoldCos: The "Forever" Owners Volaris Group represents the "Constellation Software" model, the spiritual ancestor of Bending Spoons. Volaris is an operating group of Constellation Software (CSI). 6.1 Volaris Group: The "Buy and Hold" Discipline Volaris is a "perpetual owner." They do not buy to flip; they buy to hold forever. Acquisition Pace: In 2025 alone, Volaris acquired AskCody (Denmark), Maze Feedback (Norway), Surveypal (Finland), and Bit Soft (Romania). Their appetite is insatiable. Healthcare Portfolio: Their healthcare vertical includes: Hospedia: The UK's provider of bedside terminals in NHS hospitals. A classic "unloved" asset, hardware-heavy, legacy, but with sticky, recurring revenue. Adapt IT: A South African/Global software group acquired in 2022. Saniso: Healthcare information management. The Anti-Centralisation: Unlike Access Group or Bending Spoons, Volaris often leaves acquired companies to operate autonomously ("decentralised business model").They focus on financial discipline, teaching the managers how to allocate capital and price products, rather than enforcing a single tech stack. However, the financial engine (recycling cash flow into new deals) is identical to Bending Spoons. 7. Comparative Analysis: Mapping the DNA To understand the ecosystem, we can map these players against the key Bending Spoons traits. The "Bending Spoons" Alignment Matrix Company Category "Bending Spoons" Trait Integration Strategy Key Backer The Access Group PE Platform Aggressive Integration "Access Workspace" (SSO/UI) Hg, TA Associates, GIC Main Capital Partners PE Platform Operational Alpha "Performance Excellence" Playbook Self-Managed Funds Lanas Healthcare PE Platform Roll-Up Vehicle Vertical Integration (Pharmacy/Care) TA Associates HealthHero Venture Builder Digital Front Door "Chronos" (GenAI Platform) Marcol, Claret Capital Palta Venture Builder Shared Tech Stack "Palta Brain" (Data/UA) VNV Global, Target Global CompuGroup Medical Sovereign Market Dominance Data Platform (New Line/Insight) CVC, Gotthardt Family Dedalus Group Sovereign Scale via Mega-Deals "D4P" (Dedalus 4 Patient) Ardian, ADIA Redcare Pharmacy Consumer Ecosystem Lock-in Adherence Apps (MyTherapy) Public (MDAX) Volaris Group HoldCo Capital Allocation Decentralized / Financial Discipline Constellation Software 8. Deep Insights: Emerging Trends and Future Outlook The analysis of these entities reveals several "second-order" insights that define the future of the sector. 8.1 The "Private Equityisation" of European HealthTech The most aggressive consolidators are no longer public companies. Trend: Public markets have struggled to value the "roll-up" strategy correctly, often penalising the debt and integration costs required to build these platforms. Response: Private Equity firms have stepped in to take these companies private (e.g., CompuGroup/CVC, Idox/Long Path, Servelec/Montagu/Access). This allows them to execute the "Bending Spoons" playbook, cutting costs, migrating tech and hiking prices, away from the scrutiny of quarterly earnings calls. Implication: Innovation in European HealthTech is shifting from "feature innovation" (new startups) to "business model innovation" (PE-backed platforms). The winners of the next decade will likely be portfolio companies of Hg, TA, or Ardian. 8.2 The "Digi-Physical" Convergence Pure digital health has hit a ceiling. You cannot fix a broken leg via Zoom. Trend: Consolidators are moving to own the physical delivery layer. Kry bought clinics. Cera Care is buying robotics and home care agencies. Redcare is buying delivery logistics. Insight: The "Bending Spoons" of healthcare will not just be a software company; it will be a hybrid operator that uses software to manage physical assets (clinics, robots, pills) more efficiently than incumbents. Operational Alpha will come from automating the physical world, not just the digital one. 8.3 Data as the "New Oil" for Consolidators The software is becoming a commodity; the data is the asset. Trend: Companies like CompuGroup Medical and Redcare Pharmacy are explicitly pivoting to data monetisation models. Mechanism: By owning the operating system of the doctor or the patient's adherence app, these companies sit on "Real-World Evidence" (RWE) data that is invaluable to Pharma. Future: We may see a future where the software is given away for free (or heavily discounted) to capture the data rights. This would disrupt the traditional SaaS model and favor the largest consolidators who have the scale to aggregate statistically significant datasets. 8.4 The Rise of "Sovereign" Capital The entry of ADIA (Abu Dhabi) into Dedalus and GIC (Singapore) into The Access Group signals a new phase. Insight: Sovereign Wealth Funds are looking for "infrastructure-like" returns. HealthTech consolidators, with their sticky recurring revenue and essential nature, fit this profile perfectly. Impact: This lowers the cost of capital for these consolidators, allowing them to overpay for strategic assets and squeeze out smaller financial buyers. It cements the dominance of the "Mega-Platforms." 9. Conclusion The "Bending Spoons" of European HealthTech is not a single entity, but a rapidly evolving typology. For the Consumer, it is Palta and HealthHero, who are using shared data brains to build the "Super Apps" of health. For the Hospital, it is Dedalus, utilising massive sovereign capital to roll up the continent's infrastructure. For the Doctor, it is CompuGroup Medical, pivoting from software to data. And for the Market itself, it is The Access Group and Main Capital, the financial engines that are relentlessly systematising the sector. These companies share the core Bending Spoons DNA: a belief that through scale, centralization, and operational rigor, they can generate value that far exceeds the sum of the acquired parts. As the European market matures and capital remains expensive, this consolidation wave is only just beginning. Nelson Advisors > MedTech and HealthTech M&A Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital We share our views on the latest Healthcare Technology mergers, acquisitions and partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Founders for Founders > We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide#Divestitures #Corporate #Portfolio #Optimisation #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising#BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Us @ HealthTech events October 2025 Healthcare Summit 2025, London, UK – Chairing the HealthTech M&A Panel Healthcare Summit 2025, London, UK – Chairing the HealthTech Deal Structuring Panel NHS Clinical Entrepreneur Conference, Belfast, Northern Ireland Global Health Exhibition 2025, Riyadh, Saudi Arabia – Chairing the HealthTech M&A Panel November 2025 HealthTech X Summit, London, UK – Chairing the “HealthTech predictions for 2026” Panel MedTech Europe 2025, Valletta, Malta- Speaker on the "Startups, Corporates & Hospitals: How to Build Meaningful MedTech Partnerships" panel MedTech Europe 2025, Valletta, Malta- Judge for the MedTech StartUp Pitch Awards Leaders in Health Summit 2025 December 2025 HealthTech Forward 2025, Barcelona, Spain – Moderating the Health Data Under Attack” Panel Healthcare Club, IESE Business School, Barcelona, Spain HealthInvestor Power List Awards 2025, London, UK – Judging Panel Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk

UK HealthTech & MedTech Market 2026: Mergers, Acquisitions and Fundraising Predictions Executive Summary: The Year of Strategic Convergence The United Kingdom’s Healthtech and Medtech sectors are approaching a definitive inflection point as the market transitions into 2026. Following a period characterised by post-pandemic market corrections, valuation compression and capital scarcity between 2023 and 2025, the outlook for 2026 is one of strategic acceleration and structural evolution. This report predicts that 2026 will not merely represent a cyclical rebound but a fundamental shift in the operating logic of the UK healthcare and life sciences economies, driven by the convergence of regulatory compulsion, technological maturity in generative AI and the deployment of historic levels of private capital. Our analysis, based on extensive market review, indicates that the investment landscape is moving from a "growth-at-all-costs" paradigm to a disciplined focus on "profitable efficiency" and "clinical validation." The total addressable market for mergers and acquisitions (M&A) is poised to surge, with global deal flow projected to reach $3.9 Trillion in 2026, surpassing previous records set in 2021. For the UK specifically, this liquidity will be channeled through distinct strategic corridors: the "buy-and-build" consolidation of fragmented healthcare IT infrastructure, the defensive acquisition of regulatory-compliant medical device manufacturers and the "offensive" integration of AI-driven drug discovery platforms by major pharmaceutical incumbents facing a looming patent cliff. Critically, this report identifies the state as a primary market-maker for 2026. The synchronisation of the NHS 10-Year Health Plan’s shift toward community care, the MHRA’s implementation of a new roadmap for Software as a Medical Device (SaMD) and the Treasury’s Mansion House Reforms to unlock pension capital creates a "regulatory triple-lock" that will de-risk investment in specific high-growth verticals. The following comprehensive analysis dissects these trends, offering a granular roadmap for investors, operators and policymakers navigating the UK health economy in 2026. 1. The Macroeconomic and Strategic Investment Drivers for 2026 To understand the specific trajectory of UK Healthtech M&A, one must first analyse the macroeconomic "super-cycles" that will dictate capital allocation in 2026. The period of hesitation seen in 2024 and 2025 is giving way to a release of pent-up strategic demand, driven by three powerful levers: the pharmaceutical patent cliff, the stabilisation of financing markets and the accumulation of private equity "dry powder." The Pharmaceutical Patent Cliff and the Imperative for M&A A primary structural driver for the resurgence of high-value M&A in 2026 is the pharmaceutical "patent cliff." Between 2026 and 2030, the global pharmaceutical industry faces the expiration of exclusivity patents on blockbuster drugs responsible for between $180 Billion and $400 Billion in annual revenue. Major revenue generators, including Bristol Myers Squibb’s Eliquis and Opdivo, and Merck’s Keytruda, will lose market exclusivity, opening the floodgates to generic and biosimilar competition. This impending revenue contraction is forcing pharmaceutical giants into an aggressive "offensive" M&A posture. Unlike previous cycles where R&D was primarily internal, the 2026 strategy relies heavily on external innovation acquisition to refill depleted pipelines. The Shift to TechBio: Large Pharma is increasingly looking to "TechBio", companies that combine biotechnology with machine learning, to shorten discovery timelines. The UK, hosting global leaders like Isomorphic Labs (a Google DeepMind spinout) and Exscientia, is a prime hunting ground for these acquisitions. The imperative is no longer just buying an asset (a single drug) but buying a platform (a validated discovery engine) that can generate multiple assets over time. Therapeutic Concentration: Capital will not be spread evenly. It will concentrate intensely on high-growth therapeutic areas where pricing power remains strong, specifically oncology, immunology, and neurodegenerative diseases. Furthermore, the explosion of the GLP-1 (obesity) market is driving acquirers to look for adjacent technologies in metabolic health and cardiovascular monitoring. The "Dry Powder" Release Valve The global private equity (PE) sector enters 2026 with an unprecedented volume of unallocated capital, estimated at nearly $2.5 trillion globally, with over $1 Trillion held by US investors alone. This "dry powder" represents a massive deployable force that has been largely dormant due to the valuation gaps and financing costs of 2023-2024. The 2026 Deployment Cycle: As interest rates stabilise and inflation data normalises, the cost of leverage for PE buyouts is becoming predictable again. This certainty is the trigger for deployment. In 2026, we anticipate a "deployment rush" as funds near the end of their investment periods face pressure to return capital or put it to work. This dynamic is expected to accelerate deal activity significantly in the second half of 2025, peaking in 2026. Valuation Discipline: Despite the availability of capital, the "froth" of 2021 has evaporated. The 2026 market is disciplined. Investors are demanding "profitable growth" rather than "growth at all costs." Companies with proprietary, clinically validated AI algorithms and deep integration into healthcare workflows are commanding premium valuations of 6x–8x revenue. In contrast, general HealthTech assets without clear clinical ROI are trading in the 4x–6x revenue range, creating a bifurcated market of "haves" and "have-nots". The "Buy and Build" Consolidation Engine For Private Equity in the UK and Europe, the dominant strategy for 2026 is the "Buy and Build" (B&B) model. The UK healthcare IT (HCIT) and MedTech services landscape remains highly fragmented, characterised by hundreds of small, regional SME providers. This fragmentation is inefficient but presents a classic arbitrage opportunity for PE. The Strategy: PE funds are acquiring mature "platform" companies, often in unglamorous back-office sectors like Revenue Cycle Management (RCM) or specialised testing labs and then acquiring smaller regional competitors to fold into this platform. The Arbitrage: By consolidating smaller entities (purchased at lower multiples, e.g., 4x-6x EBITDA) into a larger platform (valued at higher multiples, e.g., 10x-14x EBITDA), investors generate immediate value. The operational lever in 2026 involves digitising these consolidated entities, replacing manual processes with SaaS-based AI tools to strip out cost and improve margins. Macroeconomic Investment Drivers Summary 2026 Driver Description Impact on UK Market Patent Cliff $300B+ revenue at risk for Big Pharma (2026-2030) due to patent expiries. Drives "offensive" M&A for UK TechBio and late-stage biotech assets. Capital Overhang $2.5T global PE "dry powder" awaiting deployment. Fuels "Buy and Build" strategies in fragmented sectors like HCIT and RCM. Regulatory Cost High fixed costs of compliance (MDR/UKCA/AI Act). Forces smaller Medtech SMEs to sell to larger consolidators with compliance infrastructure. Valuation Reset Shift from revenue multiples to profitability/EBITDA metrics. Bifurcation of market: Premium for "profitable growth," down-rounds for "growth only." The Regulatory Superstructure: Policy as Market Maker In the UK’s single-payer system, government policy is not merely a constraint, it is the primary determinant of market viability. For 2026, the investment thesis is underpinned by three distinct regulatory frameworks that provide long-term visibility for investors. The NHS 10-Year Health Plan: The "Left Shift" to Community The NHS 10-Year Health Plan, effective from 2026, mandates a structural "left shift" of resources, moving care from expensive acute hospitals to community settings and the home. This is not a suggestion; it is a procurement mandate that creates winners and losers in the MedTech space. Neighbourhood Health Centres: The plan outlines the creation of "Neighbourhood Health Centres," potentially funded through new public-private partnership models. This creates a new infrastructure market for diagnostic equipment that is portable, connected, and designed for non-specialist use. Value-Based Procurement: Starting early 2026, the NHS will enforce standardised "value-based procurement" guidance. This ends the era of "cheapest price wins." Procurement decisions must now evidence long-term patient outcomes and total pathway cost savings. For UK innovators, this is a distinct advantage over cheap, commoditised imports, provided they can generate the health-economic data to prove value. Digital by Default: The NHS App is designated as the "single front door" for patient interaction by 2028, with a Single Patient Record (SPR) legislated to integrate data from validated wearables. This creates a massive, government-mandated captive audience for digital health tools that can achieve interoperability with this central spine. MHRA Regulatory Roadmap: The AI Airlock and SaMD Historically, the lack of clarity on how to regulate "adaptive" AI (algorithms that learn and change over time) has stalled investment. The MHRA’s roadmap for 2026 resolves this. Mid-2026 Implementation: The MHRA is set to implement its new framework for Software and AI as a Medical Device (SaMD/AIaMD) by mid-2026. This follows the "AI Airlock" regulatory sandbox, which has allowed the regulator to test innovative safety protocols. Divergence vs. Alignment: While the EU AI Act imposes strict, risk-based classifications that some investors fear may stifle innovation, the UK’s approach aims to be more "pro-innovation" while maintaining safety alignment with the FDA and Health Canada (via the IMDRF).This positioning is intended to make the UK a "launchpad" market for AI diagnostics. De-Risking Investment: For investors, the arrival of these regulations is a de-risking event. A startup with a clear path to UKCA marking under the new SaMD rules in 2026 is a far more attractive asset than one operating in a regulatory grey zone. Mansion House Reforms: Unlocking Domestic Capital Perhaps the most significant structural change for UK fundraising is the "Mansion House Compact." The Mechanism: The UK government has secured commitments from major pension funds to allocate at least 5% of their default defined contribution (DC) funds to unlisted equities by 2030. 2026 Impact: By 2026, the first significant flows of this capital are expected to reach the market. This addresses the critical "Series B+ gap" that has historically forced UK companies to sell early to US buyers or list prematurely on NASDAQ. Pension Mega-Funds: The proposed consolidation of fragmented pension schemes into "mega-funds" will create domestic institutional investors with the scale to write £50m-£100m checks, supporting the scaling of deep tech and life sciences companies within the UK. High-Conviction Investment Themes & Sector Analysis Based on the intersection of macroeconomic drivers and regulatory opportunities, we have identified four high-conviction investment themes for the UK market in 2026. Operational Efficiency & The RCM "Roll-Up" While clinical AI grabs headlines, the "unsexy" back-office of healthcare is where immediate financial returns are being generated. The NHS and private providers are under immense pressure to improve productivity (a 4% annual target is mandated). Revenue Cycle Management (RCM): RCM involves the software and services that manage patient registration, billing and claims processing. In the UK private sector and NHS private patient units, this is highly fragmented. The PE Thesis: Private Equity firms are aggressively deploying the "Buy and Build" model here. By acquiring a platform asset (eg. a dominant RCM software provider) and rolling up smaller service agencies, they can create a scaled entity. The value creation comes from replacing manual billing clerks with "Generative AI" agents that automate coding and claims, expanding EBITDA margins from ~15% to ~30%. SaaS Transition: The ultimate goal is to transition these businesses from "service" revenue (hourly billing) to "SaaS" revenue (recurring licenses), which commands significantly higher exit multiples. Ambient Clinical Intelligence (ACI) ACI refers to technology that passively listens to clinician-patient interactions and automatically generates structured clinical notes, coding, and letters. It is widely regarded as the "killer app" for Generative AI in healthcare because it solves the immediate crisis of workforce burnout. Strategic Alignment: The NHS 10-Year Plan explicitly references the deployment of "ambient voice technologies" to free up clinical time. Market Dynamics: This sector is moving from pilot to scale. Companies like Tortus AI (which ran pilots at Great Ormond Street Hospital) and Tandem Health are gaining traction. Investment Outlook: In 2026, we expect national-level procurement frameworks for ACI, leading to rapid adoption. Startups that have solved the specific privacy and "hallucination" risks of LLMs in a clinical setting will be prime targets for acquisition by Electronic Patient Record (EPR) incumbents (e.g., Oracle/Cerner, Epic) looking to defend their territory. The Maturation of Surgical Robotics Surgical robotics is graduating from the "early adopter" phase to the "early majority" phase, driven by the need for surgical precision and shorter recovery times (aligning with the NHS goal of reducing bed days). CMR Surgical: The Cambridge-based unicorn is the European champion in this space. Its Versius system is designed to be modular and portable, fitting the smaller operating theaters of UK and European hospitals better than the larger US-centric systems. Commercial Expansion: Having raised over $1 billion total (including a $200 million debt/equity round in late 2025 led by Trinity Capital), CMR is aggressively expanding into the US market/ 2026 Prediction: 2026 is a likely window for a major liquidity event for CMR Surgical, potentially a dual-listing IPO or a massive strategic acquisition, validating the UK's robotics ecosystem. Bioelectronic Medicine The UK is establishing itself as a global hub for "Bioelectronics", the use of miniaturised devices to modulate the body's electrical signals to treat chronic disease (e.g., rheumatoid arthritis, hypertension) without drugs. The Cluster: A unique ecosystem has formed around Stevenage and Cambridge, anchored by Galvani Bioelectronics (a GSK/Verily joint venture). Startups to Watch: Ceryx Medical is pioneering "bionic" devices that mimic the body's natural rhythms (Central Pattern Generators) to treat heart failure and respiratory conditions. 2026 Outlook: This field is moving from "science fiction" to clinical reality. 2026 will see critical trial readouts. If successful, this sector offers Big Pharma a completely new modality (electricity instead of chemistry) to mitigate the patent cliff, making these startups high-value M&A targets. Private Equity & M&A Strategy: The Consolidation Wave The M&A environment in 2026 will be defined by a "barbell" dynamic: mega-deals at the top end driven by pharma strategic imperatives, and a high volume of middle-market consolidation driven by private equity operational efficiencies. Pharmaceutical "Offensive" M&A As noted, the patent cliff is driving pharma to buy innovation. However, the target profile has shifted. From Asset to Platform: Pharma is less interested in buying a single drug (which faces its own patent expiry clock) and more interested in "platforms", technologies that can churn out multiple drug candidates. This favours "TechBio" companies. Structure: Deal structures in 2026 will be creative. Expect to see substantial use of Contingent Value Rights (CVRs) and "bio-bucks" (milestone payments) to bridge the gap between the valuation expectations of founders (anchored in 2021) and the discipline of acquirers. MedTech: The Defensive "Compliance Moat" The increasing cost of regulation (MDR, UKCA, environmental standards) is creating a "compliance moat" that protects large incumbents but drowns small SMEs. The Trend: Large players like Medtronic, Stryker, and Philips will acquire smaller UK manufacturers not just for their IP, but because the smaller firms cannot afford the overhead of maintaining global regulatory compliance. Defensive Consolidation: We expect a wave of consolidation among UK Medtech supply chain SMEs, driven by the need to achieve the scale required to absorb these fixed compliance costs. The "Clean-Up" of Cap Tables A significant, albeit painful, feature of the 2026 M&A market will be the resolution of "zombie" companies, startups that raised at unsustainable valuations in 2021 and have failed to grow into them. Down Rounds & Recapitalisations: 2026 will likely see a peak in "down rounds" and "pay-to-play" recapitalisations, where existing investors wash out early shareholders to reset the valuation for new capital. Distressed M&A: This presents an opportunity for well-capitalised PE firms and strategics to acquire high-quality IP and talent at a discount ("acqui-hires"). Fundraising Dynamics: The Rise of TechBio and Regional Clusters The Venture Capital Rebound After the "funding winter," VC investment in UK healthtech is rebounding. Data suggests that 2026 will see a sustained recovery, with H1 2025 investment levels already showing an upward trajectory. However, the criteria for funding have changed permanently. Seed Stage: Remains robust. Investors are keen to back novel science and deep tech at the earliest stages where valuations are reasonable. Series A/B (The Gap): This remains the hardest chasm. To cross it in 2026, companies must show not just "user growth" but "reimbursement traction." The question is no longer "will clinicians use it?" but "who will pay for it?" Growth Stage: Capital is available but highly concentrated. The "Mansion House" pension funds will seek to write large checks ($50m+) into a small number of "national champions" rather than spreading bets widely. The Rise of TechBio "TechBio" is the standout sector for UK venture capital. Unlike traditional biotech (high risk, binary outcome) or digital health (low barrier to entry), TechBio offers a scalable engine for discovery. Key Examples: Isomorphic Labs (London) is partnering with global pharma (Lilly, Novartis) to apply its AlphaFold technology to drug design. Exscientia (Oxford) continues to industrialise AI drug design. Valuation Premium: These companies are valued more like software companies (recurring revenue from partnerships) than biotech companies (binary risk), helping them maintain valuation premiums even in a disciplined market.7 Regional Clusters: Beyond the Golden Triangle While London, Oxford, and Cambridge (The Golden Triangle) continue to dominate, 2026 will see the maturation of the "Northern Powerhouse" clusters, supported by the government's levelling-up agenda and the NHS Plan. Leeds (Digital & Data): Leeds is solidifying its position as the UK's capital for Digital Health. Home to NHS England’s digital leadership, it recently launched the Health Innovation Leeds Incubator with a £2m boost. The city is a hub for RCM, system-level IT, and data interoperability startups. The establishment of the MHRA's new digital hub in Leeds city centre further anchors this ecosystem. Manchester (Genomics & Trials): Manchester is leveraging its large, diverse patient population and devolved health budget to become a leader in "Real World Evidence" (RWE) trials and genomics. Scotland (Medtech & Sleep): Edinburgh is emerging as a niche hub for SleepTech and wearable sensors, with companies like SnoreMetrics and Current Health (acquired by Best Buy) setting a precedent. Public Markets: IPOs and the Listings Outlook The IPO market, frozen for much of 2023-2024, is showing distinct signs of a "thaw." 2026 is projected to be a busy year for UK healthtech listings, though the venue (London vs. New York) remains a contentious strategic decision. The LSE vs. NASDAQ Dilemma For UK HealthTech ScaleUps, the choice of listing venue is critical: The NASDAQ Pull: The US market offers deeper pools of specialist capital, higher valuations, and a sophisticated analyst ecosystem that understands deep tech/biotech. For companies with a heavy US commercial focus (like CMR Surgical), NASDAQ remains the default ambition. The LSE Counter-Attack: The London Stock Exchange (LSE) is fighting back. The Mansion House reforms are designed to create a domestic bid for UK stocks. Furthermore, analysis suggests that UK micro-cap IPOs have actually outperformed their US counterparts post-listing, offering better support for companies under the $1Bn market cap mark who might get "orphaned" in the US. Prediction: In 2026, we predict a "dual-track" approach will be standard. However, the LSE may see a resurgence for mid-cap digital health companies that want to tap into the new UK pension capital pools. Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk The 2026 IPO Pipeline Several high-profile companies are positioned for potential liquidity events in 2026: CMR Surgical: With >$1B raised and significant commercial traction, CMR is the prime candidate for a blockbuster IPO. The recent $200M financing was structured to fund the push to profitability/US expansion, typically the final step before a public listing. Huma: The digital health unicorn has been executing a rapid expansion strategy, acquiring assets and winning NHS contracts. It is a strong candidate for a 2026 listing, potentially testing the LSE's appetite for digital health. Oxford Nanopore (Existing): Already public, ONT will be a bellwether for the sector. Its performance in 2026 (as it faces competition from PacBio and scales its clinical diagnostics business) will influence investor sentiment toward UK genomics. Cautionary Tales: BenevolentAI The trajectory of BenevolentAI offers crucial lessons for the 2026 class. After listing via a SPAC in Amsterdam, the company struggled with the volatility of public markets and the pressure of quarterly reporting while still in a high-R&D burn phase. The Restructuring: In 2025, BenevolentAI delisted and merged into a private structure (Osaka Holdings) to reduce administrative costs and restructure away from the public glare. The Lesson: This experience has cooled enthusiasm for SPACs and premature listings. In 2026, companies will delay IPOs until they have predictable, recurring revenues and a "bulletproof" equity story. The focus will be on "being ready to be public," not just "going public". 7. Deep Dive: Emerging Technology Frontiers SleepTech: From Consumer to Clinical Sleep technology is graduating from simple consumer trackers (like Fitbit) to clinical-grade diagnostic and therapeutic tools. Market Growth: The UK Sleep Tech market is projected to grow at a CAGR of 14.4% through 2033, reaching over $4 billion. Key Innovators: 32Co: This dental-tech startup is launching "Aerox Sleep Centres" to treat sleep apnea using custom dental devices, effectively creating a distributed clinical network. Zeus Sleep: Based in Hampshire, this startup is developing neuro-stimulation devices for snoring and sleep apnea, bridging the gap between comfort and clinical efficacy. Integration: The trend for 2026 is "SleepTech Integration"—merging professional sleep medicine with consumer wearables to allow for long-term remote monitoring of chronic conditions. Genomics and The Long-Read Revolution The UK remains a global leader in genomics. Oxford Nanopore Technologies (ONT): ONT continues to innovate with its "nanopore" sensing technology, which allows for real-time, portable DNA/RNA sequencing. In 2026, the battleground will shift to the clinical diagnostics market, where ONT is competing against US giants like PacBio and Illumina. Differentiation: ONT's ability to analyze "native" DNA/RNA (including epigenetic modifications) in real-time gives it a unique advantage in cancer diagnostics and rapid infectious disease response. Conclusion: The 2026 Investment Thesis The year 2026 represents a maturation point for the UK Healthtech and Medtech sectors. The speculative excess of the pandemic era has been washed out, replaced by a market structure defined by strategic necessity (pharma patent cliffs), operational efficiency (NHS productivity targets), and technological convergence (AI + Biology). Key Takeaways for Investors & Operators: Align with the "Left Shift": Do not fight the NHS 10-Year Plan. Investments that facilitate the movement of care from hospital to home (RPM, community diagnostics, sleeptech) have a structural tailwind. Hunt for Efficiency: In a labor-constrained NHS, technologies that automate administrative tasks (RCM, Ambient Clinical Intelligence) will see faster adoption than complex clinical decision support tools. The "Roll-Up" Opportunity: The fragmentation of the UK healthcare back-office is an arbitrage opportunity. Expect private equity to be the most active buyer in the sub-$50m deal bracket. Deep Tech Resilience: While consumer health apps face skepticism, "hard tech"—robotics, bioelectronics, and AI-driven drug discovery, retains premium valuation status due to high barriers to entry and global strategic interest. Regulatory Awareness: Success in 2026 requires navigating the "Triple Lock" of NHS Procurement, MHRA SaMD rules, and Pension Fund capital requirements. Regulatory strategy is now as important as product strategy. In summary, 2026 will be a year where capital returns to the market with conviction. It will be selective, disciplined, and focused on "national champions" that can scale globally while solving the acute productivity crises of the domestic health system. Predicted Top UK Healthtech M&A Themes 2026 Theme Strategic Driver Target Type Buyer Profile RCM Roll-Up Operational Efficiency/Recurring Revenue Billing, Coding, Inventory Mgt Software Private Equity (Buy & Build) Pharma "Reload" Patent Cliff ($300B+ at risk) Late-stage Oncology, Immunology, TechBio Platforms Big Pharma (AstraZeneca, GSK, Pfizer) Medtech Defense Regulatory Cost (MDR/UKCA) Compliance-heavy SMEs, Device Manufacturers Medtech Giants (Medtronic, Boston Sci) AI Integration Workforce Productivity Ambient Clinical Intelligence (Scribes), Workflow AI EMR Providers, Tech Giants Table 3: UK Regional Healthtech Cluster Strengths Cluster Primary Focus Areas Key Assets/Hubs 2026 Outlook Cambridge TechBio, Surgical Robotics, Bioelectronics CMR Surgical, AstraZeneca, Bioelectronics Lab Maturation of robotics ecosystem; Bioelectronic clinical readouts. London AI Drug Discovery, Digital Health, Fintech-Health Isomorphic Labs, Huma, Francis Crick Institute Focus on AI/ML applications and high-growth VC funding. Leeds Digital Health, RCM, Data Platforms NHS England Digital, Health Innovation Leeds Incubator Hub for national scale-up of digital infrastructure and system IT. Manchester Genomics, Precision Medicine, RWE Manchester Science Park, QIAGEN Leader in clinical trials and real-world evidence generation. Oxford Immunotherapy, Genomics Oxford Nanopore, Exscientia Continued leadership in spin-outs from University research Notable UK/European Healthtech Scaleups Watchlist (2026 Potential Exits/IPOs) Company Sector Status/Funding Note 2026 Outlook CMR Surgical Robotics Raised >$1B total; $200M in late 2025. Potential IPO (NASDAQ/LSE) or Strategic M&A. Huma Digital Health Unicorn status; Decentralised Clinical Trials. Potential IPO candidate. Isomorphic Labs TechBio (AI Drug Disc) Alphabet subsidiary; ext. partnerships. Strategic Partnerships / Spin-out value. Cera Care Tech-Enabled Care >$500M Revenue; Home care platform. IPO Candidate or PE Exit. BenevolentAI TechBio Delisted/Privatised in 2025. Restructuring / Private Sale. Oxford Nanopore Genomics Public (LSE: ONT). M&A Target or Acquirer of smaller peers. Zeus Sleep SleepTech Early stage; £150k recent raise. Growth funding / Strategic partnership target. Tandem Health Ambient AI Partnered with Accurx for NHS rollout. Acquisition target for larger EHR/IT vendors. Nelson Advisors > MedTech and HealthTech M&A Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital We share our views on the latest Healthcare Technology mergers, acquisitions and partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Founders for Founders > We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide#Divestitures #Corporate #Portfolio #Optimisation #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising#BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Us @ HealthTech events October 2025 Healthcare Summit 2025, London, UK – Chairing the HealthTech M&A Panel Healthcare Summit 2025, London, UK – Chairing the HealthTech Deal Structuring Panel NHS Clinical Entrepreneur Conference, Belfast, Northern Ireland Global Health Exhibition 2025, Riyadh, Saudi Arabia – Chairing the HealthTech M&A Panel November 2025 HealthTech X Summit, London, UK – Chairing the “HealthTech predictions for 2026” Panel MedTech Europe 2025, Valletta, Malta- Speaker on the "Startups, Corporates & Hospitals: How to Build Meaningful MedTech Partnerships" panel MedTech Europe 2025, Valletta, Malta- Judge for the MedTech StartUp Pitch Awards Leaders in Health Summit 2025 December 2025 HealthTech Forward 2025, Barcelona, Spain – Moderating the Health Data Under Attack” Panel Healthcare Club, IESE Business School, Barcelona, Spain HealthInvestor Power List Awards 2025, London, UK – Judging Panel Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk

The Great Valuation Pivot: From the "Rule of 40" to the "Rule of Data" in the Era of Artificial Intelligence Executive Summary The global technology and venture capital landscape is currently navigating a structural transformation of a magnitude not witnessed since the transition from on-premise software to cloud computing. As the industry approaches 2026, the financial heuristics that governed the Software-as-a-Service (SaaS) boom, most notably the "Rule of 40", are rapidly eroding in efficacy. The catalytic force behind this obsolescence is the widespread commoditisation of generative artificial intelligence (AI) algorithms. With open-source foundation models now achieving functional parity with proprietary closed-source alternatives, the value proposition of pure software code has approached zero. In this new paradigm, enterprise value is decoupling from raw revenue growth and re-anchoring to a new asset class: the Proprietary Data Moat. This report articulates the emergence of the "Rule of Data," a valuation framework that prioritises the defensibility, quality and exclusivity of the underlying data assets over the scalability of the software wrapper. We predict that in 2026, the only truly defensible data asset is high dimensional, proprietary data that cannot be scraped from the public web, with biological data emerging as the gold standard of this asset class. Through a rigorous analysis of market trends, financial disclosures from Q3 2025 and emerging architectural patterns, this report provides a roadmap for investors and operators navigating the shift from the "Rule of 40" to the "Rule of Data." The Macro-Financial Shift: The Obsolescence of the "Rule of 40" For over a decade, the "Rule of 40" served as the North Star for the software industry. It provided a simple, elegant heuristic: a healthy SaaS company’s combined revenue growth rate and profit margin (typically EBITDA or Free Cash Flow) should equal or exceed 40%. This metric governed boardrooms, dictated executive compensation, and determined valuation multiples. However, as we enter 2026, the utility of this metric has collapsed under the weight of Goodhart’s Law and the changing physics of AI economics. The Historical Utility and Mechanism of the Rule of 40 The Rule of 40 was born in an era where the primary constraint on growth was sales and marketing efficiency. It offered a standardised way to compare companies at different stages of their lifecycle. A startup growing at 100% year-over-year could justify a -60% margin, while a mature incumbent growing at 10% needed to deliver 30% margins to be considered "efficient". Strategic Trade-offs: The rule clarified the acceptable trade-offs between growth and profitability. It allowed investors to model how operational changes, such as reducing customer acquisition costs (CAC) or increasing upsells, would impact the firm’s overall health. Valuation Correlation: Historically, companies that consistently exceeded the Rule of 40 commanded significant valuation premiums. In the public markets, high performers often traded at 12–15x EV/Revenue, compared to a median of roughly 6x for the broader SaaS cohort.Companies like Doximity (55%) and Datadog historically exemplified this elite tier. The Collapse: Goodhart’s Law in 2025 By late 2025, the Rule of 40 began to fail as a predictive signal for long-term value. This failure is rooted in Goodhart’s Law: "When a measure becomes a target, it ceases to be a good measure". Artificial Optimisation: To meet the 40% threshold during the capital-constrained environment of 2023–2025, many companies slashed Research and Development (R&D) budgets. While this improved short-term EBITDA margins, it hollowed out their long-term defensibility against AI disruption. The Growth Decoupling: Data from SaaS Capital’s 2025 survey reveals a structural decline in Rule of 40 scores across the industry. The median score dropped to just 12% in Q1 2025, driven primarily by a slowdown in revenue growth that cost-cutting could not offset. The "Lumpy" Reality of AI CAPEX: The Rule of 40 fails to account for the massive, irregular capital expenditures required for AI infrastructure. Training a foundation model requires upfront GPU investments that distort EBITDA margins for quarters at a time, making the metric noisy and unreliable. The Rise of Capital Efficiency: The "Burn Multiple" As the Rule of 40 fades, a sharper metric has emerged to assess the sustainability of growth: the Burn Multiple. Defined as Net Burn divided by Net New Annual Recurring Revenue (ARR), this metric isolates the capital efficiency of growth. The New Standard: In the high-interest-rate environment of 2025 (with the Fed rate hovering around 4.0–4.25%), capital is no longer free. A Burn Multiple below 1.5x is now considered the "sweet spot," signaling that a company is generating significantly more revenue than it consumes in cash. The AI Trap: Crucially, the Burn Multiple exposes "AI-wrapper" companies that appear to be growing fast (high revenue) but are merely reselling compute at low margins (high burn). A company might show 50% growth (satisfying the Rule of 40) but have a Burn Multiple of 3.0x due to high GPU costs, revealing it as a fragile investment. The market has realized that high margins on a non-defensible product are temporary. This realisation is driving the shift toward the "Rule of Data," where the asset base—not just the P&L, determines value. The Great Commoditisation: Algorithms in the Age of Open Source To understand why data has become the primary defensible asset, one must first analyse the rapid depreciation of the algorithm itself. The year 2025 marked the "Commoditisation Event" for Generative AI, where the performance gap between proprietary models (like GPT-4) and open-source models (like Llama 3) effectively closed. The Closing of the Performance Gap In the early days of the generative AI boom (2023–2024), proprietary models held a significant advantage in reasoning, coding, and multimodal capabilities. Companies built business models around "access" to these superior models. By 2025, that advantage evaporated. Open Source Maturity: Models such as Meta’s LLaMA 3 (70B) and Mistral’s Mixtral (Mixture of Experts) now rival proprietary giants in critical enterprise tasks like summarisation, classification, and code generation. The release of LLaMA 3 70B provided developers with a model that many argue is indistinguishable from GPT-4 for 90% of use cases, yet it is free to use and modify. Specialised Dominance: Open models like Falcon (optimised for multilingual tasks) and Mistral 7B (optimised for speed and low latency) allow enterprises to deploy highly specialized agents that outperform generalist proprietary models on specific tasks. The Economic Implications for "Wrappers" This parity has devastated the "AI Wrapper" business model—startups that simply put a user interface on top of a third-party API. Zero Switching Costs: The abundance of high-quality open models means that switching costs for the underlying intelligence engine have plummeted. Enterprises in 2026 are adopting "hybrid" architectures, routing simple queries to cheap, open-source models (the 80%) and only using expensive proprietary models for complex reasoning (the 20%). Margin Compression: Companies that rely on third-party APIs have structurally lower gross margins (often 50-60%) compared to true software companies (80%+). As the underlying models become commodities, pricing power collapses, creating a "race to the bottom". The Strategic Pivot to Sovereignty For regulated industries like healthcare and finance, the "black box" nature of proprietary models is a liability. Open-source models allow for Data Sovereignty, companies can host the model within their own secure VPC (Virtual Private Cloud), ensuring that sensitive patient or financial data never leaves their control.This requirement for control further accelerates the adoption of open-source, rendering the proprietary algorithm less relevant than the secure, proprietary data it processes. The New Sovereign: Defining the "Proprietary Data Moat" In the vacuum left by the commoditised algorithm, the Proprietary Data Moat has emerged as the definitive metric for 2026. The "Rule of Data" posits that a company’s long-term enterprise value is strictly proportional to the volume, quality, and exclusivity of the data it possesses that cannot be accessed by public foundation models. Anatomy of a True Data Moat Not all data constitutes a moat. A database of public LinkedIn profiles or scraped web text is valueless because it is already included in the training sets of major models like GPT-5 or Claude. A true data moat must satisfy three rigorous criteria: Exclusivity (The "Un-Scrapable" Test): The data must be inaccessible to web crawlers. This includes proprietary biological assays, private financial transaction logs, or internal enterprise workflows. If OpenAI can scrape it, it is not a moat. Multimodality: The highest-value datasets in 2026 are those that combine disparate data types. For example, Tempus AI pairs genomic sequencing data with clinical outcome data. Neither dataset is unique on its own, but the linkage between them is extremely rare and valuable. The Feedback Loop (The Data Flywheel): The product must be designed such that every user interaction generates new training data that improves the model. This creates a "Data Flywheel" where more users lead to a better model, which attracts more users. The "1-10-100 Rule" of Data Quality The "Rule of Data" is not just about quantity; it is obsessively focused on quality. In an AI-driven system, bad data does not just cause a reporting error; it causes hallucinations and model drift, which can destroy the product's utility. The Metric: The 1-10-100 Rule has become a standard diligence framework for AI investors. It posits that verifying a record at the point of entry costs $1. Cleaning it after it has been stored costs $10. But if bad data feeds into an automated AI decision making process (like a drug target prediction or a loan approval), the failure cost is $100. Operational Consequence: Companies are now valued on their "Data Hygiene." Investors look for automated data governance platforms (like Alkymi or Moody’s tools) that ensure data is "audit-ready" and semantically consistent.A company with 10 petabytes of "messy" data is a liability; a company with 1 petabyte of structured, labeled data is an asset. Semantic Consistency and Governance For a data moat to be actionable, it must have Semantic Consistency. In large enterprises, "revenue" might be defined differently by Sales, Finance, and Marketing. AI models cannot reason across these contradictions.Therefore, the "Rule of Data" demands a unified semantic layer where data definitions are standardised. Companies that have achieved this "semantic coherence" can deploy agents that actually work, creating a defensible barrier against competitors who are still struggling with data silos. The Architecture of Defensibility: AI-Native vs. AI-Enabled The "Rule of Data" has catalysed a bifurcation in the software market, dividing companies into two distinct architectural classes: AI-Native and AI-Enabled. This distinction is not merely semantic; it drives a massive divergence in valuation multiples. Comparative Analysis of Architectures The following table synthesises the structural differences between these two business models: Feature AI-Native (The New Premium) AI-Enabled (The Legacy SaaS) Core Strategy AI is the foundation; the business cannot exist without it. AI is a feature added to existing workflows (e.g., a "Copilot"). Data Flow Data collection is intrinsic to product design; every click trains the model. Data is siloed; limited feedback loops; often relies on third-party APIs. Valuation Multiple 20x - 50x Revenue 5x - 10x Revenue Gross Margins 90% (Automation replaces human labor/COGS) 70-80% (Standard SaaS Hosting) Moat Source Proprietary Data + Continuous Learning Loops Brand + Distribution + Workflow Lock-in Revenue/Employee ~$3.5M (High operational leverage) ~$200K (Standard SaaS leverage) Scaling Dynamics Unlimited scaling via compute. Linear scaling via headcount (Sales/CS). Examples Midjourney, Recursion, Perplexity Salesforce Einstein, Microsoft Copilot The Economics of the AI-Native Firm The most striking metric in the "Rule of Data" era is Revenue per Employee. Traditional SaaS companies average around $200,000–$300,000 in revenue per employee. AI-Native companies, by contrast, are achieving numbers upwards of $3.5 million per employee. Midjourney serves as the archetype: with a team of fewer than 100 people, it generates hundreds of millions in revenue. This hyper-efficiency is possible because the "product" is generated by the AI, not by human service delivery. Valuation Implications: Investors pay a premium for this leverage because it implies that as the company scales, costs will grow linearly (compute) while revenue grows exponentially. This breaks the traditional linear constraints of the "Rule of 40," creating a "Rule of Data" where the asset (the model/data) does the work. Sector Case Study: The Industrialisation of Biology (TechBio) The prompt identifies Proprietary Biological Data as the "only defensible asset." This assertion is grounded in the fact that biological data is high-dimensional, incredibly expensive to generate, and legally protected. Unlike code or text, you cannot "hallucinate" a correct biological interaction; you must observe it in the physical world. Recursion Pharmaceuticals: The 65-Petabyte Moat Recursion Pharmaceuticals (RXRX) is the standard-bearer for the "Rule of Data" in biotech. The Asset: Recursion has industrialized the wet lab, using robots to conduct millions of experiments per week. This has generated a proprietary dataset exceeding 65 petabytes of biological and chemical data. This includes "phenomics", high-resolution images of cells reacting to various chemical compounds. The Flywheel: This data feeds their foundation models, MolE (chemistry) and Molphenix (phenomics). These models predict how a new drug candidate will interact with a target in silico (virtually), allowing them to screen billions of compounds without touching a pipette. Financial Reality: In Q3 2025, Recursion reported revenue of $5.18 million, a significant miss against the expected $16.95 million. However, the stock did not collapse to zero because investors are valuing the platform, not the quarterly drug sales. The company holds $785 million in cash, providing a runway through 2027. Validation: The moat was validated by a $30 million milestone payment from Roche/Genentech for the delivery of a "whole genome neuromap." This transaction proves that the data itself—not just the drug—is a monetizable asset. Tempus AI: The Clinical-Genomic Nexus Tempus AI (TEM) illustrates the power of clinical data aggregation. The Asset: Tempus has built a library of over 9 million patient records and 4 million genomic profiles. The moat lies in the linkage: they know the patient's genetic mutation (genomics) AND how they responded to treatment (clinical outcome). This paired dataset is estimated to be 60x larger than public datasets like The Cancer Genome Atlas. Business Model & Valuation: Tempus operates a "data-enabled" business model. It runs diagnostic labs (low margin) to generate data, which it then licenses to pharma companies (high margin) for drug discovery. In 2025, this model drove revenue guidance to $1.26 billion (82% growth), with the company trading at ~10.5x 2025 Sales. This multiple is significantly higher than traditional diagnostic labs, reflecting the premium placed on its proprietary data moat. Absci: Generative AI for "De Novo" Design Absci (ABSI) represents the frontier of "Generative Biology." The Technology: Unlike Recursion (which screens existing compounds), Absci uses generative AI to design new antibodies from scratch ("de novo"). Strategic Pivot: In late 2025, Absci executed a strategic pivot, reallocating resources to its internal pipeline (ABS-201) and away from lower-value services. Despite reporting negligible revenue of $0.4 million in Q3 2025, the company maintains a cash runway into 2028. The Thesis: Investors are betting that Absci’s data, derived from screening billions of antibody interactions, will allow it to "solve" antibody design, reducing development times from years to months. The valuation is almost entirely derived from the optionality of its data platform rather than current cash flows. Emerging Players: CardiaTec and Meliora The ecosystem is expanding beyond the giants: CardiaTec is building a multi-omics dataset specifically for cardiovascular disease, utilising human heart tissue data that is impossible to replicate without a massive clinical network. Meliora Therapeutics is building a "mechanism of action" atlas for oncology, using machine learning to correct mischaracterised drugs. Their "molecular fingerprint" method relies on a proprietary data engine that serves as a discovery flywheel. Beyond Biology: Data Moats in Other Sectors While biology offers the starkest example of the "Rule of Data," the principle applies to any sector where data is scarce, private, and complex. Financial Services: The Sovereign Data of Moody’s In the fintech sector, Moody’s demonstrates how legacy incumbents can pivot to become AI powerhouses. The Moat: Moody’s possesses decades of proprietary financial data, credit ratings, and risk assessments that are not available on the open web. The Application: By training AI models on this private corpus, Moody’s created an "AI Research Assistant" that reduces financial analysis time by 30%. Because the model is grounded in proprietary, verified data, it avoids the hallucinations common in generic finance bots, creating a defensible "high-trust" moat. Private Markets: Unstructured Data as a Moat Companies like Alkymi and 7 Chord are capitalising on the opacity of private markets. Alkymi uses AI to extract data from unstructured private equity documents (PDFs, emails). The moat here is the access to these private documents and the proprietary ontology built to understand them. A generic LLM cannot interpret a "capital call notice" with the precision required for financial settlement without this specialised training data. Marketing Tech: Zeta Global’s Data Cloud Zeta Global provides a counter-example in the marketing space. The Asset: Zeta manages a proprietary data cloud of consumer intent signals. Valuation: Trading at a discount to high-growth peers, Zeta is viewed by some analysts as an "undervalued gem" because its data moat allows for precise targeting that survives the death of the third-party cookie. The model projects a 49% return based on this data-driven efficient growth. The Investor’s Dilemma: Valuation Frameworks in 2026 As the market pivots from the Rule of 40 to the Rule of Data, the toolkit for valuing companies is being rewritten. The following frameworks summarise how investors are pricing assets in 2026. The New Due Diligence Checklist Investors are moving beyond simple P&L analysis to audit the asset base itself. Data Provenance & Exclusivity: Is the data proprietary, or is the company a "wrapper" around public data? Investors look for the "Data-to-Model Ratio", how much unique internal data is used to fine-tune the model vs. base training data. Burn Multiple: As a proxy for product-market fit. A Burn Multiple > 2.0x suggests the company is "buying revenue" rather than growing through data network effects. Revenue Quality: A shift from Gross Merchandise Value (GMV) to "Revenue Quality." AI-driven revenue (high margin, automated) is valued higher than human-driven revenue (low margin, service-heavy). Valuation Multiples by Category The market has stratified into distinct valuation tiers based on defensibility. Category Valuation Multiple (EV/Revenue) Defensibility Profile Traditional SaaS 3.9x - 6.0x Low. Commoditized by AI code gen. AI-Enabled SaaS 5.0x - 10.0x Medium. Incremental efficiency gains. AI-Native / TechBio 12.0x - 30.0x High. Proprietary data creates a "hard" moat. Sovereign Data Platforms Premium (Outliers) Extreme. National security / Health critical assets. VC Sentiment and Deal Structure The "Flight to Quality" is real. In Q3 2025, venture funding concentrated heavily in late-stage, proven winners. Eleven "mega-deals" accounted for a significant portion of capital, with AI funding representing 46% of all VC dollars. Investors are willing to pay massive premiums for companies that have proven their "Data Flywheel," while seed-stage funding for "wrapper" startups has dried up. The Counter-Thesis: Distribution and Reasoning No strategic shift is without its detractors. A significant counter-narrative exists that challenges the supremacy of the "Data Moat," arguing instead for Distribution and Reasoning. The "Distribution is King" Argument Skeptics argue that in a world where intelligence is a commodity, the entity that owns the customer wins. Workflow Lock-in: If a company like Salesforce (CRM) or Microsoft (Office) integrates a "good enough" open-source model into their existing workflow, they can crush a superior AI-native competitor. The "switching cost" of moving data out of Salesforce is higher than the benefit of a slightly better AI model. The "Verb" Moat: Being the default option (e.g., "Google it", "Slack me") creates a brand moat that technical superiority cannot breach. Investors betting on this thesis prioritise companies with massive install bases over those with unique data. The "Reasoning" Overhang A more technical counter-argument comes from AI researchers like Bob McGrew (formerly of OpenAI), who argue that Reasoning (System 2 thinking) is the next frontier, not just data scale. Less Data Needed: As models get better at "reasoning," they may need less training data to perform tasks. "Zero-shot" learning could theoretically allow a generic model to perform a specialised task (like reading a contract) without needing a proprietary dataset of 10,000 contracts. Commoditization of Agents: If reasoning becomes solved, then AI agents themselves will become commodities priced at the cost of compute. In this scenario, the only value capture is in the physical world (Robotics/Bio) or in "Sovereign" data that requires trust (Healthcare/Finance). Synthesis: The "Data-Distribution Flywheel" The most sophisticated investors in 2026 are looking for the intersection of both. The ultimate winner is the company that uses Distribution to acquire customers, which generates Data, which improves the product, which drives more Distribution. xAI (Grok): Elon Musk’s xAI is cited as a prime example. It has "Distribution" (access to X/Twitter’s 600M users) AND "Data" (the real-time feed of global conversation). This combination creates a moat that neither a pure model company (like Anthropic) nor a pure social network can easily replicate. Conclusion: The New Rules of the Road The transition from 2025 to 2026 marks the end of the "Growth at All Costs" era and the beginning of the "Defensibility at All Costs" era. The "Rule of 40," while still a useful hygiene metric for financial solvency, has been superseded by the Rule of Data as the primary determinant of enterprise value. Strategic Imperatives for 2026: For Founders: Stop pitching the algorithm. Pitch the data. Demonstrate how your product captures unique, high-dimensional data that improves your model in a closed loop. If your data is available on the public web, you do not have a company; you have a feature. For Investors: Audit the data pipeline. Apply the "1-10-100 Rule" to assess technical debt. Scrutinise the "Burn Multiple" to ensure that growth is organic and product-led, not fuelled by unsustainable ad spend. For Enterprises: Embrace open source. The cost of intelligence is trending to zero. Use LLaMA and Mistral for 80% of your workflows to preserve margins, and reserve proprietary spend for the 20% of tasks where reasoning or security is paramount. In the final analysis, the "Rule of Data" is a return to first principles. In a digital world where copying code is free, value accrues to the scarcity of truth. Whether that truth is the binding affinity of a protein, the creditworthiness of a borrower, or the intent of a consumer, the companies that own the Source of Truth will inherit the future. Summary of Key Metrics for 2026 Metric Definition Benchmark Rule of Data Valuation based on proprietary data volume, exclusivity, and feedback loops. Data Flywheel active. Burn Multiple Net Burn / Net New ARR < 1.5x (Excellent) 1-10-100 Rule Cost of Data Quality (Prevention vs Correction vs Failure). Automated Governance in place. Revenue/Employee Total Revenue / Full Time Employees >$1M (AI-Native Target) Rule of 40 Revenue Growth + EBITDA Margin > 40% (Baseline Hygiene only) The "Rule of 40" is dead. Long live the Rule of Data... Nelson Advisors > MedTech and HealthTech M&A Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital We share our views on the latest Healthcare Technology mergers, acquisitions and partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Founders for Founders > We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide#Divestitures #Corporate #Portfolio #Optimisation #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising#BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Us @ HealthTech events October 2025 Healthcare Summit 2025, London, UK – Chairing the HealthTech M&A Panel Healthcare Summit 2025, London, UK – Chairing the HealthTech Deal Structuring Panel NHS Clinical Entrepreneur Conference, Belfast, Northern Ireland Global Health Exhibition 2025, Riyadh, Saudi Arabia – Chairing the HealthTech M&A Panel November 2025 HealthTech X Summit, London, UK – Chairing the “HealthTech predictions for 2026” Panel MedTech Europe 2025, Valletta, Malta- Speaker on the "Startups, Corporates & Hospitals: How to Build Meaningful MedTech Partnerships" panel MedTech Europe 2025, Valletta, Malta- Judge for the MedTech StartUp Pitch Awards Leaders in Health Summit 2025 December 2025 HealthTech Forward 2025, Barcelona, Spain – Moderating the Health Data Under Attack” Panel Healthcare Club, IESE Business School, Barcelona, Spain HealthInvestor Power List Awards 2025, London, UK – Judging Panel Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk

This Week in European MedTech and HealthTech: 5th December 2025 The first week of December 2025 was defined by two major themes: the domination of RSNA 2025 by European imaging giants and a landmark public private investment partnership to fuel the continent's life sciences sector. In Chicago, Siemens Healthineers and Philips unveiled their next-generation flagship platforms, signaling a definitive shift toward "eco-friendly" high-field MRI and AI-integrated spectral CT. On the investment front, Angelini Ventures and the European Investment Bank (EIB) signed a €150 Million agreement to co-invest in European health startups, a critical move to keep deep-tech innovation within the EU. Below is a detailed analysis of the week’s key developments. 1. Innovation & Product Launches (RSNA 2025 Highlights) The Radiological Society of North America (RSNA) annual meeting (Dec 1–5) is the world's premier imaging event. European heavyweights used this global stage to launch their most significant products for the 2026 fiscal year. Philips (Netherlands): The "Helium-Free" Pivot Philips continued its aggressive push into sustainable imaging with the launch of BlueSeal Horizon, the world’s first helium-free 3.0T MRI platform.​ Significance: Historically, 3.0T magnets (used for high-resolution brain and musculoskeletal imaging) required thousands of litres of liquid helium. BlueSeal Horizon uses a permanently sealed magnet requiring only 7 litres, eliminating the risk of helium shortages—a major supply chain vulnerability for European hospitals in recent years. AI Integration: Philips also introduced Verida, an AI-enabled spectral CT system. Unlike previous iterations where spectral analysis was a post-processing step, Verida integrates AI directly into the imaging chain to reduce noise and improve clarity in real-time. ​Siemens Healthineers (Germany): Interventional Radiology Focus Siemens focused on expanding the clinical utility of MRI beyond diagnostics into interventional radiology (IR). Magnetom Free.XL: Launched this week, this 0.55T MRI scanner is designed specifically for the interventional suite. Its wider bore (opening) allows surgeons to perform procedures inside the scanner and the lower magnetic field strength (0.55T) reduces heating risks for metallic interventional devices.​ AI Software: The company unveiled the Syngo.CT Coronary Cockpit, a new software module that automates the analysis of coronary CT angiography (CCTA) scans, aiming to clear the backlog of cardiac diagnostics in overburdened EU healthcare systems.​ Other European Players Agfa HealthCare (Belgium): Shifted its entire narrative to "Imaging without Barriers," showcasing a fully cloud-native Enterprise Imaging Cloud. This SaaS model allows hospitals to stream diagnostic-quality images to remote radiologists, directly addressing the radiologist shortage crisis in the UK and Germany.​ Guerbet (France): As RSNA’s "Country of Honour," France had a dedicated pavilion. Guerbet highlighted its digital health expansion, emphasizing AI tools for contrast dose management alongside its traditional pharma portfolio.​ 2. Investment & Financial News Angelini Ventures & EIB: A €150 Million "Deep Tech" LifelineIn a major boost for the sector, Angelini Ventures (the VC arm of Angelini Industries) and the European Investment Bank (EIB) signed a partnership to deploy €150 million into European biotech and medtech startups.​ Structure: Each entity will contribute €75 million. Strategic Intent: The fund is explicitly designed to address the "Series B gap" in Europe, where promising startups often sell to US competitors due to a lack of local growth capital. First Move: The partnership’s first confirmed co-investment is in Adcytherix, a French company developing Antibody-Drug Conjugates (ADCs) for cancer therapy. (Note: Adcytherix’s Series A round closed in October, but this week’s news formalised the EIB’s strategic role in that syndicate).​ M&A Activity: GE Healthineers Acquires Intelerad While GE is US-headquartered, this deal has significant ramifications for the European market. On December 2, GE Healthineers announced the acquisition of Intelerad Medical Systems for approximately $2.3 billion. Intelerad is a major provider of medical imaging software. This move consolidates the PACS/VNA market, challenging European incumbents like Agfa and Sectra by creating a more vertically integrated GE imaging ecosystem.​ 3. Regulatory & Policy Landscape The "Digital Omnibus" Reaction On December 4, MedTech Europe (the industry trade body) formally responded to the European Commission’s "Digital Omnibus" proposal.​ Context: The Commission recently proposed delaying specific "high-risk" AI compliance rules for medical devices to prevent a market bottleneck. Industry Stance: MedTech Europe welcomed the delay but warned it is insufficient. They are lobbying for a "targeted postponement" of the MDR (Medical Device Regulation) re-certification deadline as well, arguing that delaying the AI Act alone solves only half of the compliance burden facing manufacturers in 2026. UK MHRA & Digital Mental Health The UK’s regulator, the MHRA, issued new guidance this week on digital mental health technologies.​ Impact: The guidance provides a clearer pathway for "software as a medical device" (SaMD) in mental health to gain UKCA marking. It was released alongside a £2 million funding injection to speed up the approval of these specific tools, responding to the NHS's growing waitlists for mental health services. Germany: eCTD Validation Effective December 1, 2025, Germany’s BfArM (Federal Institute for Drugs and Medical Devices) made new eCTD (electronic Common Technical Document) validation criteria mandatory. While technical, this is a critical compliance update for any medtech company whose products involve drug-device combinations submitted in Germany. >>> The first week of December 2025 highlighted a pivotal shift in European HealthTech regulation, with the European Commission moving to unlock patient data for AI training, a long-awaited reform for the sector. In the UK, the NHS continued its digital integration with a major push into home diagnostics (HIV) and mental health regulation. On the startup front, capital is flowing into "verticalised AI" (specialised tools for specific medical niches) rather than general platforms. This was exemplified by the €3.2M seed round for La Fraise (dental AI) and the strategic partnership between Neuraxpharm and mjn-neuro to launch a seizure-prediction wearable. Below is the detailed breakdown of the week’s key trends. 1. Regulation & Policy: The Data & AI Shift The most consequential news this week concerns the legal framework for building health AI in Europe. The "Digital Omnibus" & GDPR Reform News broke this week regarding the European Commission's "Digital Omnibus" proposal, which includes a critical update to GDPR known as the "Data Unlock." The Change: The proposal seeks to classify the training of AI models using personal data as a "legitimate interest." Impact: Currently, HealthTech startups struggle to train algorithms on patient data without explicit, granular consent from every individual. If passed, this reform would lower the legal barrier for accessing Real-World Data (RWD), potentially accelerating the development of predictive models across the EU.​ UK Mental Health "AI Airlock" In a significant move for digital therapeutics (DTx), Wellcome announced a £2 million funding injection for the UK’s regulators (MHRA and NICE) to build a dedicated "AI Airlock" for mental health apps.​ What it is: A regulatory sandbox that allows companies to test digital mental health tools with the regulator before a full NHS rollout. Why it matters: Mental health apps have historically faced a "wild west" of regulation. This funding aims to create a clear, safety-first pathway for these tools to become prescribed medical devices within the NHS by 2028. 2. Investment & Startup Activity VC activity this week signalled a strong appetite for "vertical SaaS"—software platforms dedicated to specific medical specialties. Spotlight: La Fraise (France) La Fraise ("The Strawberry") emerged from stealth with a €3.2 million Seed round backed by 20VC, Seedcamp, and Kima Ventures.​ The Founders: The team includes four alumni from Doctolib, Europe’s most valuable HealthTech company. The Product: An "AI-native operating system" specifically for dental practices. It automates administrative workflows (quotes, insurance, financing) to free up clinical time. Traction: The startup claims to already have 1,200 dentists using the platform, facilitating over 30,000 treatments. This rapid adoption suggests a high demand for specialty-specific administrative AI. Ireland’s Record Year A report released on December 2 revealed that Irish health tech and life sciences companies raised a record €491.3 million in 2024 (reported retrospectively this week). This confirms Ireland's growing status as a key hub for medtech and digital health innovation, rivalling traditional centres like the UK and Germany.​ 3. Innovation & Strategic Partnerships Neuraxpharm x mjn-neuro (Spain/Germany) European CNS specialist Neuraxpharm announced a major strategic partnership with Spanish neurotech startup mjn-neuro to launch EPISERAS.​ The Tech: A wearable medical device (earpiece) combined with an AI app that predicts epileptic seizures before they happen. Status: The device has received its CE Mark (Class IIa) and UKCA certification. Roadmap: While announced now, the full European commercial rollout is scheduled for the second half of 2026. This moves Neuraxpharm from a pure-play pharma company into the "digital pharma" space. NHS Digital Updates (UK) HIV Home Testing: On December 1 (World AIDS Day), the UK government unveiled a new HIV Action Plan. A core component is the integration of HIV home-testing kits directly into the NHS App, making it easier for millions of users to order discreet tests.​ Social Care Digitisation: On December 4, the Department of Health announced that 80% of social care providers in England have now adopted digital social care records (DSCRs), a critical step toward a "Single Patient Record" that connects hospitals with nursing homes.​ 4. Event Highlights: European Digital Health Summit The European Digital Health Summit took place in Madrid (Dec 1–2), bringing together policymakers and industry leaders.​ Key Themes: The discussions focused heavily on the European Health Data Space (EHDS)and the "One Health" approach. Takeaway: The consensus from the summit is that while the technical infrastructure for EHDS is being built, the governance (who accesses what data and for what purpose) remains the primary bottleneck for cross-border digital health in Europe. Nelson Advisors > MedTech and HealthTech M&A Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital We share our views on the latest Healthcare Technology mergers, acquisitions and partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Founders for Founders > We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide#Divestitures #Corporate #Portfolio #Optimisation #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising#BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Us @ HealthTech events October 2025 Healthcare Summit 2025, London, UK – Chairing the HealthTech M&A Panel Healthcare Summit 2025, London, UK – Chairing the HealthTech Deal Structuring Panel NHS Clinical Entrepreneur Conference, Belfast, Northern Ireland Global Health Exhibition 2025, Riyadh, Saudi Arabia – Chairing the HealthTech M&A Panel November 2025 HealthTech X Summit, London, UK – Chairing the “HealthTech predictions for 2026” Panel MedTech Europe 2025, Valletta, Malta- Speaker on the "Startups, Corporates & Hospitals: How to Build Meaningful MedTech Partnerships" panel MedTech Europe 2025, Valletta, Malta- Judge for the MedTech StartUp Pitch Awards Leaders in Health Summit 2025 December 2025 HealthTech Forward 2025, Barcelona, Spain – Moderating the Health Data Under Attack” Panel Healthcare Club, IESE Business School, Barcelona, Spain HealthInvestor Power List Awards 2025, London, UK – Judging Panel Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk

MedTech Innovator 2026 Programme MedTech Innovator 2026 Nelson Advisors has been invited to mentor and judge the MedTech Innovator 2026 programme alongside a panel of esteemed US and European industry executives. Now in its 13th year, MedTech Innovator, the world’s largest medtech accelerator continues to identify the most promising medical device, diagnostic, and digital health startups developing innovative tools to improve patient care. https://medtechinnovator.org/ MedTech Innovator is the world's largest accelerator for medical device, digital health, and diagnostic companies. Our mission is to improve patients' lives by accelerating the growth of companies transforming healthcare worldwide. "According to Silicon Valley Bank’s CipherBio, MedTech Innovator is the largest accelerator of Life Science companies in the world. The dominant part of our portfolio is Medical Devices, in addition to our leadership position as an accelerator of diagnostics, digital health, and life science tools technologies. 93% of our portfolio are still in business or have been acquired, and 86% of our companies have raised equity financing. In Q1 2023, approximately 30% of all funds raised in the medtech sector went to a graduate of MedTech Innovator." Our corporate partners include leading manufacturers like Johnson & Johnson, Dexcom, NIPRO Medical Corp., Olympus Medical Systems Group, W. L. Gore & Associates, Asahi Intecc, Edwards Lifesciences, Fujikura, Jabil Healthcare, Maxim Integrated Ventures. and many others. They participate as thought leaders, application reviewers, event judges, and accelerator mentors. Hundreds of investors like RCT Ventures, Aphelion Capital, Life Science Angels, Healthtech Capital, Sofinnova Partners, Vensana, Treo, Hunniwell Lake Partners, Seroba Life Sciences participate as application reviewers, mentors, and judges. https://medtechinnovator.org/about-us/ MedTech Innovator is the world’s largest accelerator of medical technology companies, with a mission to improve the lives of patients by accelerating the growth of transformative health care startups. Along with its sibling programs, BioTools Innovator and MedTech Innovator Asia Pacific, the organization provides founders with mentorship, exposure to industry leaders, and access to funding opportunities. Each year, thousands of startups compete for a place in the programs’ cohorts, gaining global visibility and connections that help bring their innovations to market faster. Nelson Advisors invited to join the MedTech Innovator 2026 Programme as a Judge and MedTech Mentor MedTech Innovator MedTech Innovator is a nonprofit global competition and accelerator that has grown since 2013 into the largest and one of the highest‑performing accelerators for medical device, digital health, and diagnostic startups worldwide. It combines a global pitch competition, a virtual accelerator, and showcase events tied to major industry conferences to help early‑ to growth‑stage companies access capital, customers, and strategic partners.​ Origins and Founding MedTech Innovator was founded by Paul Grand in 2013 as an internal program within RCT Ventures, an early‑stage life science investment firm where he was a managing director. The program emerged in response to a perceived “Series A crunch” in medtech, where early‑stage device and diagnostics companies struggled to secure follow‑on capital despite strong technology, prompting industry stakeholders to back a structured accelerator model.​ Spin‑out and Nonprofit Status Between 2013 and 2016, MedTech Innovator operated within RCT Ventures before being spun out as an independent nonprofit organization based in Los Angeles in 2016–2017. At incorporation, it formalized a board including representatives from MedTech Innovator, Research Corporation Technologies, Johnson & Johnson Development Corporation, and AdvaMed, reinforcing its positioning as an industry‑backed, founder‑friendly platform.​ Program Structure and Activities The core offering is a four‑month, mainly virtual accelerator running from June to October, into which roughly 50 or more of the most promising startups are selected from a global applicant pool often exceeding 1,000 companies. Participants receive targeted mentorship, non‑dilutive funding opportunities, and high‑visibility showcase slots at the WSGR Medical Device Conference and The MedTech Conference (powered by AdvaMed), plus access to corporate executives, investors, payers, providers, regulators, and an extensive alumni network.​ Growth, Scale and Impact MedTech Innovator is widely described as the largest and most impactful medtech accelerator globally, and also as the largest accelerator of life science companies with a portfolio that is predominantly medical devices but also includes diagnostics, digital health, and life science tools. By mid‑2020s reports, hundreds of companies have passed through its programs, alumni have brought hundreds of products to market, and they have collectively raised many billions of dollars in follow‑on capital, with a very high proportion still active or acquired relative to typical startup survival rates.​ Global Expansion and APAC Program Beyond its original U.S.‑focused activities, MedTech Innovator has expanded globally, including launching MedTech Innovator Asia Pacific, which runs a regional accelerator and a dedicated U.S. Market Access Program for APAC medtech companies. Across regions, the organization positions itself as an industry‑wide platform and “premiere showcase” that curates a global pipeline of high‑quality medtech startups for strategic partners, investors, and acquirers. Nelson Advisors > MedTech and HealthTech M&A Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital We share our views on the latest Healthcare Technology mergers, acquisitions and partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Founders for Founders > We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide#Divestitures #Corporate #Portfolio #Optimisation #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising#BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Us @ HealthTech events October 2025 Healthcare Summit 2025, London, UK – Chairing the HealthTech M&A Panel Healthcare Summit 2025, London, UK – Chairing the HealthTech Deal Structuring Panel NHS Clinical Entrepreneur Conference, Belfast, Northern Ireland Global Health Exhibition 2025, Riyadh, Saudi Arabia – Chairing the HealthTech M&A Panel November 2025 HealthTech X Summit, London, UK – Chairing the “HealthTech predictions for 2026” Panel MedTech Europe 2025, Valletta, Malta- Speaker on the "Startups, Corporates & Hospitals: How to Build Meaningful MedTech Partnerships" panel MedTech Europe 2025, Valletta, Malta- Judge for the MedTech StartUp Pitch Awards Leaders in Health Summit 2025 December 2025 HealthTech Forward 2025, Barcelona, Spain – Moderating the Health Data Under Attack” Panel Healthcare Club, IESE Business School, Barcelona, Spain HealthInvestor Power List Awards 2025, London, UK – Judging Panel Nelson Advisors - HealthTech and MedTech Investment Banking

Nelson Advisors partner Lloyd Price co authors the Oxford University Venture Capital Network 'Insights into Digital Health' Report Exec Summary Nelson Advisors partner Lloyd Price co-authored the Oxford University Venture Capital Network: Insights into Digital Health Report with Ava Chan - DPhil candidate in Biology, Ellena O’Keeffe - MSc in Applied Cancer Science, Sili (Bobby) Qiu - DPhil candidate in Organic Chemistry, Adriana Mordente - DPhil candidate in Biology, Aneshka Moudry - MChem Chemistry. About Oxford University Venture Capital Network (OXVC) The Oxford University Venture Capital Network (OXVC) is a network of start-up founders, investors, and entrepreneurial Oxford students, supported by Oxford Science Enterprises and Presidio Ventures. For many students and founders, venture capital is a mysterious, complex, and inaccessible industry. We’re here to demystify it. VCs shape the future of the world through their investments, changing how we socialise, bank, travel, access healthcare, and beyond. However, VC is one of the least diverse industries. Women constitute only 30% of VC personnel in the UK and ethnic diversity is low. We want to change that. We take raw student talent, ambition, and vision and work directly with VC funds to provide a grounding in the theoretical and practical aspects of funding innovative ideas through to profitable outcomes. We nurture future innovators. Insights into Digital Health Report Below is an executive summary of the Oxford University Venture Capital Network: Insights into Digital Health Report: Digital Health definition We define Digital Health as the development and use of digital technologies making their way into products and companies for the first time to improve health outcomes. Market, Innovation & Funding Landscape The largest market for digital health is in North America, whereas the fastest growing market is in the Asia-Pacific region. The biggest innovation hotspots constitute London, followed by Oxford, Cambridge and Southampton. Technology and Segment Deep Dives We provide in-depth market analysis into the digital health industry segmented into Data Collection & IT, Diagnostics, Disease management and Digital therapeutics. Data Collection and IT As healthcare systems shift towards outcomes-based models, the demand for integrated data platforms that support personalised patient care, real-time data analytics, and efficient healthcare delivery is surging. New entrants in this space should focus on developing innovative, scalable health tech solutions that align with Value-Based Care principles, ensuring regulatory compliance and addressing unmet needs in patient care and data management. Market strategies should emphasise collaborating with existing healthcare players, demonstrate clear clinical and cost-efficiency outcomes and ensure seamless integration with existing healthcare systems. B2B segment to dominate the market due to increasing strategic collaborations and the building of verticals. Diagnostics (Point of Care Technology) The increasing prevalence of chronic diseases and an ageing population underscore the importance of Point of Care Technology (POCT) implementation into primary care clinics. Molecular diagnostics technology is the fastest-growing segment within POCT. POCT is a competitive market and could potentially limit product innovation and market expansion. The primary users and beneficiaries of POCT over the next five years will be doctors in hospitals and clinics, who demand a high volume of devices and consumables. Disease Management The CKD management market is large and growing, driven by technological innovation and increasing demand for advanced treatments. Regulatory approval in key markets like the US and UK is crucial for the adoption of new technologies. The field faces challenges such as treatment costs, access to care, and the complexity of disease management. Startups and investors active in this space have significant opportunities for innovation and growth, with the potential for lucrative exits through acquisitions or IPOs. This landscape scan provides a foundational understanding of the venture capital dynamics in the CKD management sector, highlighting the opportunities for innovation and investment in this critical area of healthcare. Digital Therapeutics (DTx) DTx has great potential, and it has a growing market. At the same time, the market is getting crowded and has a few regulatory hurdles. DTx can extend care to a wider group of people compared to traditional medicine. The main challenges include the lack of regulatory and cybersecurity infrastructure for this emerging field, and limited clinical adoption due to lack of awareness or education. Reimbursement model hinders DTx clinical translation as patients become hesitant to try out advanced technologies. DTx startups' go-to-market strategies need to address a broad range of stakeholders in the DTx ecosystem to gain successful market entry, and clinical adoption can be improved through digital health education. It is foreseeable that DTx will be integrated into emerging technologies such as smart implants and have greater emphasis on preventive care . Updates from the Oxford University Venture Capital Network Receive the latest and greatest Oxford and worldwide entrepreneurial news and events straight to your inbox. - https://mailchi.mp/295f16a3929d/signup Oxford University Venture Capital Network

Key European HealthTech and MedTech M&A Predictions for 2026 The European HealthTech and MedTech M&A landscape in 2026 is poised for significant strategic acceleration, marking a transition from cautious, volume-driven dealmaking to high-value, transformative transactions. Deal flow is consolidating toward fewer but substantially larger deals, with market participants prioritising scalable technologies with robust clinical validation and AI integration capabilities. Market Outlook and Deal Activity Forecast Global M&A volumes are expected to surge, with Goldman Sachs projecting deal flow could reach $3.9 Trillion in 2026, potentially surpassing the 2021 record. European healthcare M&A demonstrated remarkable resilience in 2025, with an 87% spike in deal value reaching €31.8 Billion in the first half of 2025, despite an 8% decline in deal count. This "bigger cheques, fewer bets" approach signals a maturing market where acquirers prioritise high-quality, high-value assets. Investment bankers and dealmakers expect more transactional activity in healthcare in 2026 than was evident in 2025, with large listed healthcare businesses likely to prune their portfolios, creating carve-out opportunities for investors capable of such transactions. Half of European dealmakers surveyed expect M&A activity levels to increase over the next 12 months, despite considerable market volatility. The European HealthTech market is valued at approximately $96.68 Billion in 2025 and projected to reach $222.22 Billion by 2030, representing an impressive 18.11% CAGR. The European medical technology market itself stands at roughly €170 billion in 2024, with Europe maintaining a positive medical devices trade balance of €5 Billion. Strategic Drivers of M&A Activity Artificial Intelligence as the Primary Catalyst The single most potent catalyst driving deal value across both sectors is the urgent necessity to acquire advanced AI and Generative AI capabilities. AI captured 58% of Europe's total digital health funding in 2024, with investors demonstrating heightened enthusiasm for AI-enabled ventures due to their transformative potential in diagnostics, operations, and treatment personalisation. Companies with proprietary AI algorithms, clinically validated solutions, and deep integration into existing healthcare workflows command premium valuations of 6x to 8x revenue, compared to the general HealthTech range of 4x to 6x revenue. Key AI-driven M&A targets include: · Ambient Clinical Intelligence and AI scribes for clinical workflow automation · AI-powered diagnostics and medical imaging platforms · Revenue Cycle Management platforms enhanced with automation Pharma Patent Cliff Pressure A major structural driver is the looming pharmaceutical patent cliff, with $180–400 Billion in branded drug sales at risk from patent expiries between 2026 and 2030. Major blockbuster drugs including Eliquis (2026), Keytruda, and Opdivo are losing exclusivity, forcing pharmaceutical giants to pursue aggressive M&A to fill pipeline gaps. This has shifted dealmaking philosophy from "buying revenue" to "buying innovation," with preclinical and Phase I asset deals surging to account for over a quarter of total deal value in 2024, compared to just 8% for commercial-stage assets. Notable deals reflecting this trend include J&J's $14.6 Billion acquisition of Intra-Cellular, Merck's $10 Billion deal for Verona Pharma (a UK firm), and Sanofi's $9.5 Billion purchase of Blueprint Medicines. Regulatory Environment as Competitive Filter The convergence of high regulatory costs and technical complexity under MDR/IVDR, the AI Act, and EHDS is acting as a powerful competitive filter. High fixed compliance costs disproportionately strain under capitalised SMEs, accelerating strategic acquisitions by larger multinational incumbents like Medtronic and Philips that possess the internal compliance infrastructure to absorb these costs efficiently. Key regulatory timelines for 2026: · Full high-risk AI system requirements under the EU AI Act take effect August 2026 · AI systems intended as medical devices must complete conformity assessment by August 2026 · EHDS implementation phases continue, with Digital Health Authorities established by 2027 MedTech Europe has urged the European Commission to provide regulatory relief by early 2026, including targeted postponement of re-certification requirements to avoid bottlenecks. Mega-Deal Predictions and Sector Focus Areas Mega-Deals on the Rise The year 2026 is projected to witness a substantial increase in mega-deals ($5 Billion and above), following momentum established in 2025. Strategic imperatives for incumbents are two fold: defensive acquisitions to counter macroeconomic and regulatory headwinds (including the impact of GLP-1 drugs on certain device markets) and offensive acquisitions to secure high-growth therapeutic areas including neuro vascular, advanced diagnostics and AI data platforms. High-Priority Acquisition Targets Sector Focus Area Key Buyers HealthTech: Provider Operations/RCM AI-enabled revenue cycle management and billing automation PE firms, health systems HealthTech: Clinical DTx/SaMD Clinically validated digital therapeutics with clear reimbursement pathways Pharma/Biotech, Large Payers MedTech: Surgical Robotics Autonomous/AI-driven surgical platforms MedTech incumbents MedTech: Diagnostics AI-powered diagnostics and imaging platforms Tech giants, pharma HealthTech: Telemedicine Scalable digital care delivery platforms Strategic buyers, PE Notable recent transactions establishing precedent include: · Hims & Hers acquisition of Zava (UK-based) for European market expansion across UK, Germany, France, and Ireland, expected to be accretive by 2026 · Intuitive Surgical's acquisition of distribution businesses in Italy, Spain, Portugal, Malta, and San Marino, closing in 2026 · Zimmer Biomet's acquisition of Monogram Technologies for AI-driven orthopaedic robotics · Teleflex's €760 million acquisition of Biotronik's vascular intervention unit Private Equity's Expanding Role Private equity engagement has been particularly strong, with sponsor buyout deals in European healthcare increasing by 276% to €29.6 Billion year-to-date 2025 compared to 2024. The volume of European healthcare PE deals reached a record high in 2025, surpassing the previous peak set in 2021. Key PE strategies for 2026: Buy-and-Build Consolidation: The most critical strategy for PE funds deploying capital into European HealthTech in 2026 is the Buy-and-Build model. The structural fragmentation within HealthTech and MedTech makes it an ideal environment for B&B strategies, allowing PE to create scale through platform acquisitions and technology integration. AI-Native Mergers: PE firms are strategically merging legacy healthcare businesses with AI-native startups, exemplified by New Mountain Capital's plan to combine three companies into an AI-based revenue cycle management platform. Club Deals: PE firms are partnering with corporate buyers to "double down" on specific therapeutic areas, sharing risk and leveraging deeper sector expertise. Major PE fund closings include Sofinova Partners' €650 Million Capital XI fund, specifically targeted at early-stage HealthTech and MedTech companies—one of the largest early-stage healthcare funds in Europe recently. Geographic Hotspots Europe is expected to continue absorbing market share from regions like the Americas, which saw declines in H1 2025. The UK led European digital health funding with $409 Million in Q3 2025, followed by Germany, France, and the Nordics. United Kingdom: The UK market is strategically important and forecasted to register the highest CAGR in European Health IT. The NHS 10-Year Health Plan introduces standardised value-based procurement guidance for devices and digital products starting early 2026, with approximately £10 Billion annual MedTech spend now shifting from cost-driven to outcome-driven purchasing. Nordic Countries: Continue to demonstrate strength in AI-driven oncology and preventive health, with deals like Helsinki-based Gosta Labs' €7.5 Million Seed round for clinical-grade AI. Germany, France, and Netherlands: Remain consistent performers, though Germany and Italy experienced deal value declines in H1 2025. European Health Data Space (EHDS) Impact The EHDS, adopted in March 2025, represents the EU's most ambitious attempt to unlock health data potential while safeguarding fundamental rights. This regulation is expected to be transformative for M&A by creating new opportunities for data-driven acquisitions. Implementation timeline: · 2025–2027: Adoption of implementing acts defining technical standards and interoperability requirements · By 2029: Primary use regulations enabling cross-border EHR access · By 2031: Secondary use of health data fully operational for research and AI training For M&A purposes, the EHDS creates acquisition opportunities around: · Dynamic data consent solutions and data flow infrastructure · Health data access body (HDAB) service providers · AI platforms leveraging structured, cross-border health data The EU has committed €14.4 million through the EU4Health-2026 call specifically for health data for biotech innovation leveraging the EHDS. Five Megatrends Shaping 2026 Based on comprehensive analysis, five dominant megatrends are forecast to shape European HealthTech and MedTech in 2026: Electric Medicine (Bioelectronic Medicine): Expansion of neurotechnology and bioelectronic devices beyond deep-brain stimulation to include sophisticated Brain-Computer Interfaces and non-invasive neuromodulation. SleepTech Integration: Convergence of professional sleep medicine and consumer wearables, part of broader remote patient monitoring and personalised healthcare Ambient Clinical Intelligence: Widespread adoption of AI scribes and ambient voice technologies in European clinical settings, tightly regulated by the EU AI Act Defence MedTech and Supply Chain Resilience: Heightened focus on strategic preparedness and secure, local manufacturing following geopolitical challenges Dynamic Data Consent Models: Implementation of granular, user-controlled consent models under EHDS, enabling data sharing for AI development while ensuring GDPR compliance Valuation Multiples and Investment Trends Current European HealthTech valuation multiples show a "cautious yet discernible rebound": Category EV/Revenue Multiple EV/EBITDA Multiple General HealthTech 4x–6x 10x–14x AI-driven solutions 6x–8x+ Premium above range Data monetisation platforms 5.5x–7x Premium above range Value-based care solutions 5.5x–7x Premium above range Smaller/unprofitable startups 3x–4x N/A Key drivers of valuation premiums include proprietary AI algorithms, recurring revenue models, regulatory clarity and compliance, and integration with Electronic Health Records. Strategic Recommendations For Founders and Sellers: · Prioritise AI integration and clinical validation to command premium valuations · Ensure regulatory compliance with MDR/IVDR and prepare for AI Act obligations by August 2026 · Develop interoperability with EHR systems and EHDS standards (OMOP, FHIR) For Strategic Acquirers: · Focus H1 2026 on regulatory infrastructure plays ahead of EHDS implementation · Target AI-native platforms that can be integrated across existing portfolios · Consider bolt-on acquisitions in high-growth verticals: mental health tech, femtech and preventive care For Private Equity: · Deploy Buy-and-Build strategies leveraging market fragmentation · Target Series B+ companies with proven unit economics for M&A-centric exits · Form club deals with corporate buyers in attractive therapeutic areas The fundamental market prediction for 2026 is that the alleviation of antitrust risk, coupled with significant capital availability, empowers CEOs to execute acquisitions that secure platform-level AI technology and address deep-seated portfolio vulnerabilities, marking a definitive shift toward complex, necessary transformation in European HealthTech and MedTech. Nelson Advisors > MedTech and HealthTech M&A Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital We share our views on the latest Healthcare Technology mergers, acquisitions and partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Founders for Founders > We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide#Divestitures #Corporate #Portfolio #Optimisation #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising#BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Us @ HealthTech events October 2025 Healthcare Summit 2025, London, UK – Chairing the HealthTech M&A Panel Healthcare Summit 2025, London, UK – Chairing the HealthTech Deal Structuring Panel NHS Clinical Entrepreneur Conference, Belfast, Northern Ireland Global Health Exhibition 2025, Riyadh, Saudi Arabia – Chairing the HealthTech M&A Panel November 2025 HealthTech X Summit, London, UK – Chairing the “HealthTech predictions for 2026” Panel MedTech Europe 2025, Valletta, Malta- Speaker on the "Startups, Corporates & Hospitals: How to Build Meaningful MedTech Partnerships" panel MedTech Europe 2025, Valletta, Malta- Judge for the MedTech StartUp Pitch Awards Leaders in Health Summit 2025 December 2025 HealthTech Forward 2025, Barcelona, Spain – Moderating the Health Data Under Attack” Panel Healthcare Club, IESE Business School, Barcelona, Spain HealthInvestor Power List Awards 2025, London, UK – Judging Panel Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk

Who are the leading boutique M&A investment bankers advising European Digital Health, HealthTech and MedTech Founders? Executive Summary: Strategic Advisory Landscape: European Digital Health, HealthTech, MedTech M&A The European healthcare technology landscape is undergoing a profound structural transformation, characterised by a bifurcation of asset classes, a shift in valuation paradigms and an increasing reliance on specialised advisory services. As the market transitions from the liquidity fuelled exuberance of previous cycles to a "flight to quality" environment in 2024 and 2025, the role of the investment banker has evolved from a facilitator of transactions to a strategic architect of corporate destiny. This report provides analysis of the leading boutique M&A investment bankers advising European Digital Health, HealthTech, and MedTech founders. It challenges the traditional "league table" hierarchy, positing that for high-growth, innovation led companies, specialised sector expertise and deep industrial connectivity often outweigh the balance sheet capabilities of global bulge bracket firms. The analysis distinguishes between the "Industrial MedTech" and "Digital Health" advisory tracks, identifying the key individuals and firms that dominate these distinct yet converging ecosystems. The findings suggest that a new class of "super-boutiques", firms like Nelson Advisors, Clipperton and Arma Partners, has emerged to bridge the gap between venture capital exits and private equity roll-ups, offering a level of technological fluency that traditional generalist banks struggle to match. Furthermore, the consolidation of advisory firms themselves, exemplified by Stifel's acquisition of Bryan Garnier and Houlihan Lokey's expansion, signals a maturation of the European middle market. The Strategic Context of European HealthTech M&A (2024–2025) Market Bifurcation: Industrial MedTech v Digital Health The architecture of Mergers and Acquisitions (M&A) advisory within the European HealthTech and MedTech sectors has undergone a radical structural transformation throughout the fiscal periods of 2024 and 2025. Founders and boards must now recognise that the selection of an M&A advisor is no longer a function of prestige alone, but of strategic alignment with one of two diverging paradigms: the "Industrial MedTech" track and the "Digital Health" track. The Industrial MedTech Track: This segment remains rooted in hardware, regulatory pathways (MDR/IVDR) and reimbursement strategies. It is characterised by slower, capital-intensive R&D cycles and exits to large strategic conglomerates (eg. Stryker, Boston Scientific). Advisors here must possess deep clinical understanding, global supply chain insights, and the ability to navigate complex regulatory environments such as the CE Mark process and FDA approvals. The Digital Health Track: This segment operates on SaaS metrics, recurring revenue models (ARR), and data monetisation strategies. It includes Health IT, AI-driven diagnostics, and patient engagement platforms. Exits here are increasingly driven by Private Equity (PE) technology funds and hybrid strategic buyers looking for software capabilities. The "Flight to Quality" and Valuation Realism The 2024-2025 period is defined by a "flight to quality" and a rigorous emphasis on clinical utility over theoretical potential. Following the correction of valuation cycles, acquirers are prioritising "concentrated value," driven by the imperative to acquire advanced AI capabilities that can deliver immediate operational efficiencies. The divergence between deal volume and deal value underscores this trend. While overall deal volumes have experienced pressure, assets with proven technology, particularly in AI and digital infrastructure, continue to command premium valuations. This environment favours advisors who can articulate complex technological value propositions rather than simply managing a competitive auction process. The Rise of Distressed M&A and Consolidation A significant but under-reported trend is the rise of distressed M&A. High interest rates and tighter venture funding have exposed weaker players, leading to a surge in "take-private" transactions and distressed asset sales. It is estimated that 25% to 35% of M&A deals in the UK involve companies selling for less than the total capital invested into them. This "triage" market requires bankers skilled in restructuring, rapid accelerated M&A, and complex carve-outs. The Advisory Spectrum: Categorisation of Firms To understand the competitive landscape, one must categorise the advisory firms based on their operational model, deal size focus and sector depth. The following table provides a strategic segmentation of the advisory landscape. Comparative Analysis of Advisory Categories Category Typical Deal Size Primary Value Proposition Key Firms The Titans (Bulge Bracket) >$1 Billion Global balance sheet, IPO execution, cross-border scale. Goldman Sachs, J.P. Morgan, Morgan Stanley, Bank of America. The Mid-Market Global Connectors $100M - $1B Transatlantic reach, institutional depth, high deal volume. Jefferies, Houlihan Lokey, Lincoln International, Stifel. The Specialist Boutiques $10M - $500M Niche expertise (e.g., Digital Health, Biotech), founder-centric. Nelson Advisors, Clipperton, WG Partners, Mavie Technologies. The Digital Economy Powerhouses $100M - $1B+ Tech-first approach applied to healthcare, software metrics focus. Arma Partners, GP Bullhound.4 Leading Specialist Boutiques: The "Founders for Founders" & Tech Experts For European founders of Digital Health and innovative MedTech companies, specialist boutiques often offer a more tailored high-touch service than the bulge bracket banks. These firms are typically led by former entrepreneurs or career specialists who understand the nuances of code, clinical data, and regulatory hurdles. Nelson Advisors: The Entrepreneurial Architects Nelson Advisors has carved out a unique position as a "Founders for Founders" advisory firm. Unlike traditional investment banks staffed by career financiers, Nelson Advisors is led by individuals who have built, scaled and exited their own HealthTech ventures. This operational DNA allows them to bridge the gap between technical founders and financial buyers. Core Specialisations: Digital Health, HealthTech, Healthcare AI, Medical Device Cybersecurity. Geography: UK, Europe, North America. Deal Size: Lower Mid-Market ($10M - $250M). Key Leadership Lloyd Price (Co-Founder & Partner): A central figure in the UK and European digital health scene. Price brings over 25 years of experience, having founded and exited multiple ventures, including Zesty (acquired by Induction Healthcare). His background spans consumer internet (Yahoo, Kelkoo) and deep HealthTech, giving him a rare ability to translate consumer engagement metrics into healthcare valuations. He serves as a Health Executive in Residence at UCL Global Business School for Health, further cementing his academic and strategic influence. Price is frequently cited as an expert on the "AI Premium" and the intersection of consumer technology and clinical pathways. Paul Hemings (Co-Founder & Partner): Hemings brings extensive corporate finance experience, including $50+ billion in M&A and equity transactions across global markets. His background includes co-founding Neutrally, a venture focusing on chronic lifestyle disease, which complements the firm's focus on metabolic health and longevity. His expertise is pivotal in structuring complex deals involving cross-border entities. Strategic Differentiation & Market Insights Sub-Sector Granularity: Nelson Advisors goes beyond generic "healthcare" labels, specialising in highly specific high-growth verticals like Healthcare Cybersecurity, Healthcare AI, and Medical Device Cybersecurity. This is critical in a market where generalist investors often struggle to underwrite technical risks associated with data privacy and algorithmic liability. The "Dual Advisory" Thesis: The firm posits that modern HealthTech M&A requires a hybrid approac, understanding both the clinical pathway and the software stack. Their "Founders for Founders" model is designed to guide early-stage companies through the "Series A crunch" and towards strategic exits to larger platforms. Valuation Methodology (Nov 2025): Nelson Advisors is a primary source of data on valuation multiples. As of November 2025, they report a significant widening in the spread between "average" and "premium" assets. Premium AI & Data Assets: Companies with proprietary algorithms (e.g., drug discovery, imaging AI) are commanding revenue multiples of 6.0x – 8.0x+. Value-Based Care Tech: Platforms enabling risk-bearing models trade at 5.5x – 7.0x Revenue. Standard HealthTech SaaS: Growing digital health SaaS companies trade at 4.0x – 6.0x Revenue. Distressed Assets: Unprofitable startups with high burn rates are seeing significant valuation compression, trading at 3.0x – 4.0x Revenue or lower. This data indicates that advisors must position their clients either as "must-have" AI infrastructure to capture revenue multiples or as disciplined "Rule of 40" companies to capture robust EBITDA multiples. Clipperton: The Tech-Centric Research Powerhouse Clipperton has established itself as a premier advisor for the European technology ecosystem, with a rapidly growing practice in HealthTech. The firm views Digital Health primarily through the lens of technology, applying SaaS metrics (CAC, LTV, Churn) to healthcare businesses. Core Specialisation: SaaS, HR Tech in Healthcare, Growth Financing, Digital Health. Geography: Pan-European (France, DACH, UK). Deal Size: Growth Capital to Mid-Market M&A.4 Key Leadership Nicolas von Bülow (Co-Founder & Managing Partner): A veteran of the European tech advisory scene, von Bülow has overseen over 200 transactions since co-founding the firm in 2003. His focus on Software and Deep Tech allows him to advise HealthTech companies where the value driver is proprietary code or AI algorithms rather than traditional medical devices. He is a frequent commentator on the intersection of private equity and tech innovation. Antoine Ganancia (Managing Partner): Ganancia leads the HealthTech practice, driving the firm's research initiatives and managing complex cross-border transactions. His team is responsible for the influential European Health Tech Monitor reports. Dr. Nikolas Westphal (Partner, Head of Germany): Westphal is responsible for the firm's acceleration in the DACH region, advising on landmark deals involving German and Swiss companies. Strategic Differentiation & Recent Transactions Research-Led Advisory: Clipperton distinguishes itself with high-quality proprietary research. Their European Health Tech Monitor Q1 2024 analysed valuation benchmarks and funding trends, providing clients with data-driven arguments for valuation premiums. This research capability allows them to frame narratives around "digital sovereignty" and "AI integration" that resonate with strategic buyers. The "Dual Advisory" Capability: Clipperton pairs healthcare specialists with technology bankers to cover the Digital Health spectrum. This is essential for VC exits where the value driver is proprietary code or data architecture rather than traditional EBITDA metrics. Notable Transactions: Hublo (France): Clipperton acted as sole financial advisor to Hublo, a leading provider of digital HR solutions for healthcare, on its investment by Five Arrows (Rothschild & Co's investment arm).This deal highlights Clipperton's ability to position healthcare workforce management as a high-growth SaaS vertical. myClubs (Austria/Switzerland): Clipperton advised myClubs on its sale to Urban Sports Club, creating a pan-European leader in corporate fitness and health. Smartlook (Czech Republic): Advised on the sale to Cisco, demonstrating their reach into Deep Tech and analytics. Arma Partners: The Digital Economy Heavyweight Arma Partners operates at the upper end of the boutique spectrum, often competing directly with bulge bracket firms for billion-dollar mandates. In 2023, Arma was acquired by Mediobanca to create a digital economy franchise, yet it retains its independent boutique culture and leadership. Core Specialisation: Digital Health SaaS, Private Equity Exits, Large-Cap Tech. Geography: Global (London, Munich, New York). Deal Size: Mid-to-Large Cap ($100M - $1B+).4 Key Leadership Paul-Noël Guély (Founder & Managing Partner): Guély is a titan of the European tech advisory landscape. He has steered the firm to advise on over $10 billion in cumulative deal value in record years. His strategic vision focuses on the "Digital Economy," encompassing everything from FinTech to HealthTech. He emphasises that healthcare is just one vertical where "big data" and digital transformation are creating substantial value. Daniel Fugmann: A key contact for Digital Health deals, focusing on PE exits and software assets. Strategic Differentiation & Deal Track Record (2025) Scale and Reach: Arma is capable of executing massive cross-border transactions that require significant leverage finance and regulatory structuring. They focus on "high-conviction" transactions, large, complex deals such as corporate carve-outs or pan-European platform creations. The "Platform" Strategy: Arma excels at advising on "roll-up" strategies where PE firms acquire a platform asset to consolidate a fragmented market. Recent 2025 Transactions Totalmobile (November 2025): Arma advised Totalmobile, a field service management software provider for healthcare and public sectors, on its sale to Five Arrows and DBAG. Totalmobile's technology helps over 500,000 mobile workers, and the deal facilitates international expansion. Solvinity (November 2025): Advised Solvinity, a managed cloud service provider with deep public sector/healthcare expertise, on its sale to Kyndryl. This deal underscores Arma's strength in the "Cloud/Security" intersection within healthcare. 3Cloud (November 2025): Advised 3Cloud (Azure services) on its sale to Cognizant, highlighting the demand for cloud-native platforms that can deploy AI at scale. FundApps (July 2025): Advised on the investment from FTV Capital. While FinTech-focused, the compliance monitoring technology has parallel applications in highly regulated health environments. WG Partners: The Life Sciences Capital Markets Specialists WG Partners is distinct from the pure M&A boutiques in its heavy focus on capital markets (ECM) and corporate advisory for listed life sciences companies. They are the go-to advisors for UK biotech firms navigating the complexities of the London Stock Exchange (LSE) and AIM. Core Specialisation: Life Sciences, Biotech, Public Markets (AIM/LSE), Capital Raising. Geography: UK focus with global reach. Deal Size: Small to Mid-Cap Public and Private. Key Leadership Nigel Barnes: A seasoned life sciences banker with deep relationships in the UK institutional investor base. Claes Spång: Specializes in capital raising and corporate advisory, helping biotech firms structure their equity stories for public markets. Strategic Differentiation & Recent Activity Capital Raising Dominance: WG Partners is prolific in secondary fundraises and private placements, which are the lifeblood of pre-revenue biotech companies. Recent Transactions (2024-2025) Rezolute (April 2025): Acted as Financial Advisor for a $96.9 million transaction. Imricor (March 2025): Financial Advisor for a A$70 million raise. Imricor specialises in MRI-guided ablation products, a niche medtech segment. Scancell (December 2024): Advised on an £11.3 million secondary fundraise. ViroCell Biologics (December 2024): Managed a private placement for this cell and gene therapy manufacturer. Oxford BioDynamics (January 2025): Managed a £7 million secondary fundraise. Public-to-Private & Dual Tracks: WG Partners plays a critical role in "dual-track" processes where a company might consider an IPO versus a trade sale. Their work with companies like Redx Pharma and Oxford BioMedica highlights their entrenchment in the UK life sciences ecosystem. The Mid-Market Global Connectors This category includes firms that have grown through acquisition or aggressive expansion to offer global reach while maintaining a mid-market focus. They are essential for deals requiring transatlantic connectivity (selling European assets to US buyers). Houlihan Lokey: The Consolidator Houlihan Lokey has aggressively expanded its European healthcare footprint, notably through the acquisition of GCA Altium, which significantly bolstered its technology and healthcare coverage. Core Specialization: Mid-Market M&A, Capital Raising, Healthcare Services, MedTech. Geography: Global, with strong European growth (UK, DACH). Key Leadership Paul Tomasic (Managing Director & Head of European Healthcare): Based in London, Tomasic is a thought leader on European healthcare M&A. He emphasises the shift towards "concentrated value" and the "flight to quality," advising clients to focus on profitability and clinical utility. He actively comments on the "take-private" trend, noting that public markets have undervalued European healthtech assets relative to private valuations. Andrew Murray-Lyon: Director based in London, supporting the expansion of the practice.28 Strategic Differentiation Sector Depth: Houlihan Lokey avoids generalist labels, maintaining dedicated teams for specific sub-sectors like "Payor-Focused IT," "Provider-Focused Technology," and "Wellness- and Disease-Specific Technology". This granularity allows them to speak the language of specialised buyers. Market Insights: Tomasic identifies a "structural transformation" in 2024-2025 where acquirers are prioritizing assets with "proven technology" in AI and digital infrastructure over those with merely theoretical potential. 4.2. Stifel (incorporating Bryan Garnier): The Transatlantic Platform Stifel's acquisition of Bryan Garnier & Co in 2023 was a landmark consolidation in the European advisory market, combining Stifel's US distribution power with Bryan Garnier's deep European technology and healthcare relationships. Core Specialisation: Growth Tech, Healthcare, Cross-Border M&A, ECM. Geography: Global, with deep roots in France and Germany via acquisitions. Key Leadership Olivier Garnier: Co-Founder of Bryan Garnier, now Chairman of Stifel Europe. He retains a focus on client engagement and growing the pan-European platform. Healthcare Team: The legacy Bryan Garnier team brought 20+ investment bankers and equity research analysts specialized in European healthcare. Strategic Differentiation Full-Service Offering: Post-acquisition, the firm offers a comprehensive suite including M&A, equity capital markets (IPOs), and debt private placements. This "one-stop-shop" is attractive for growth-stage companies planning a US IPO or exit. European Roots, US Reach: The firm bridges the gap for European companies like Galapagos and BioArctic seeking US capital or buyers. The combination has led to participation in over 500 European technology and healthcare transactions since 2020. Clearwater International: The Mid-Market Executor Clearwater is a powerhouse for mid-sized deals, particularly those involving private equity. They were named "Corporate Financier of the Year" at the 2024 HealthInvestor Awards. Core Specialisation: Mid-Market Deal Execution, Private Equity exits. Geography: Pan-European. Deal Size: Avg €60M - €100M. Key Leadership David Weavers (Partner & Head of Healthcare): A key figure in the UK mid-market, Weavers has led the team to complete record deal volumes. Mark Taylor (UK CEO): Supports the broader strategic direction of the healthcare practice. Strategic Differentiation Volume Execution: Clearwater excels at process management for mid-market assets. In the qualifying period for their recent award, they completed 18 international deals totaling €1.6bn, with 10 of those deals completed by the UK team. Private Equity Connectivity: They are deeply embedded in the PE community, making them an ideal advisor for secondary buyouts or bolt-on acquisitions. Valuation Dynamics and Market Trends (2025) The advisory landscape is inextricably linked to the underlying valuation environment. Advisors are currently navigating a market defined by strict valuation bifurcation and regulatory complexity. The AI Premium vs. The Profitability Discount According to Nelson Advisors' November 2025 analysis, the spread between "average" and "premium" assets has widened significantly, creating a two-speed market. HealthTech Valuation Multiples (November 2025) Asset Class Valuation Metric Range Strategic Driver Premium AI & Data EV / Revenue 6.0x – 8.0x+ Proprietary algorithms, clean data sets, "must-have" infrastructure. Value-Based Care Tech EV / Revenue 5.5x – 7.0x Platforms enabling risk-bearing models and cost reduction. Hybrid Telehealth EV / Revenue 5.0x – 7.0x Mature platforms with both virtual and in-person capabilities. Standard HealthTech SaaS EV / Revenue 4.0x – 6.0x Growing digital health SaaS with average retention/margins. Profitable HealthTech EV / EBITDA 10x – 14x Established firms with >20% EBITDA margins ("Rule of 40"). Unprofitable/Early Stage EV / Revenue 3.0x – 4.0x Startups with high burn rates or unclear ROI; severe compression. This data indicates that advisors must position their clients either as "must-have" AI infrastructure to capture revenue multiples or as disciplined "Rule of 40" companies to capture robust EBITDA multiples. Companies "stuck in the middle", burning cash with generic tech, face severe valuation compression. Regulatory Headwinds: The AI Act and GDPR The European regulatory environment is a double-edged sword currently driving strategic M&A activity. The AI Act Delay: In November 2025, the European Commission proposed delaying the enforcement of "high-risk" AI rules for medical devices to avoid a "dual regulatory burden" with the MDR (Medical Device Regulation). While this offers a reprieve, it creates uncertainty for product roadmaps. Advisors are helping clients navigate this period by focusing on "technical alignment" value propositions. GDPR Reform ("Data Unlock"): New proposals to classify "training AI models" as a "legitimate interest" under GDPR could unlock real-world data (RWD) for HealthTech startups. This significantly increases the strategic value of companies holding large, longitudinal patient datasets, making them attractive targets for Pharma and Big Tech. The Return of the "Mega-Deal" and Roll-Ups 2025 has seen the return of large "high-conviction" transactions. Private Equity firms are executing "roll-up" strategies, acquiring established tech start-ups to build dominant conglomerates.Advisors like Arma Partners and Houlihan Lokey are particularly active here, structuring complex platform deals. Conclusions and Future Outlook The landscape of M&A advisory for European Digital Health and MedTech founders is no longer a monolith of generalist banking. It has evolved into a highly specialised ecosystem where the choice of advisor acts as a signal of the company's strategic intent. For the "Unicorn" Track: Founders targeting multi-billion dollar exits or IPOs are still best served by the Titans (Goldman Sachs, J.P. Morgan) for their global distribution, but increasingly often with a specialist boutique like Arma Partners or Jefferies acting as co-advisor to provide sector narrative depth. For the "Tech Exit" (SaaS/AI): Clipperton and Nelson Advisors dominate the narrative for companies where the value lies in code, data and recurring revenue. Their ability to translate healthcare metrics into tech valuations is their primary competitive advantage. Nelson Advisors' specific focus on "Founders for Founders" resonates with early-stage entrepreneurs facing the Series A or Series B crunch. For the "Clinical" Exit: Van Lanschot Kempen and WG Partners remain the standard-bearers for life sciences and biotech, where understanding the science is prerequisite to understanding the value. Their dominance in capital markets (secondary raises, dual tracks) makes them indispensable for listed UK and Benelux biotechs. For Cross-Border Complexity: Mavie Technologies (Asia) and the merged Stifel/Bryan Garnier entity (US) offer critical infrastructure for companies looking to bridge continental divides. Outlook for 2025-2026 The market is expected to see continued consolidation among advisors themselves. We can anticipate further acquisition of specialist boutiques by mid-market aggregators seeking to bolster their AI and Digital Health credentials. The era of the generalist healthcare banker is ending; the era of the sub-sector specialist has arrived. Furthermore, as the "AI Premium" becomes the primary driver of M&A value (commanding 8x+ revenue multiples), advisors will increasingly need to employ data scientists and technical experts alongside bankers to effectively due diligence and market their clients. Nelson Advisors > MedTech and HealthTech M&A Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital We share our views on the latest Healthcare Technology mergers, acquisitions and partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Founders for Founders > We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide#Divestitures #Corporate #Portfolio #Optimisation #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising#BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Us @ HealthTech events October 2025 Healthcare Summit 2025, London, UK – Chairing the HealthTech M&A Panel Healthcare Summit 2025, London, UK – Chairing the HealthTech Deal Structuring Panel NHS Clinical Entrepreneur Conference, Belfast, Northern Ireland Global Health Exhibition 2025, Riyadh, Saudi Arabia – Chairing the HealthTech M&A Panel November 2025 HealthTech X Summit, London, UK – Chairing the “HealthTech predictions for 2026” Panel MedTech Europe 2025, Valletta, Malta- Speaker on the "Startups, Corporates & Hospitals: How to Build Meaningful MedTech Partnerships" panel MedTech Europe 2025, Valletta, Malta- Judge for the MedTech StartUp Pitch Awards Leaders in Health Summit 2025 December 2025 HealthTech Forward 2025, Barcelona, Spain – Moderating the Health Data Under Attack” Panel Healthcare Club, IESE Business School, Barcelona, Spain HealthInvestor Power List Awards 2025, London, UK – Judging Panel Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk

'Internet of Health' to breakthrough in 2026 Introduction: The Emergence of the Internet of Health (IoH) The healthcare sector is currently witnessing a paradigm shift of historical magnitude, transitioning from a reactive, hospital-centric model to a proactive, continuous, and patient-centric ecosystem. At the heart of this transformation lies the "Internet of Health" (IoH), a term that describes the convergence of consumer electronics, clinical diagnostics and cloud computing. Unlike the broader Internet of Things (IoT), which encompasses everything from smart refrigerators to industrial sensors, or the hospital-bound Internet of Medical Things (IoMT), the IoH represents a distinct domain where patient-generated health data (PGHD) from consumer wearables, smartwatches, smart rings, connected scales and blood pressure cuffs, is elevated to the status of clinical evidence. The trajectory of this domain is defined by a struggle for legitimacy. For over a decade, consumer wearables were dismissed by the medical establishment as "fitness gadgets", toys that produced noisy, unreliable data that served only to induce anxiety in the "worried well" and overload clinicians with irrelevant information. However, recent technological advancements, rigorous clinical validation studies, and evolving regulatory frameworks are dismantling this skepticism. Devices that once only counted steps are now FDA-cleared to detect atrial fibrillation (AFib), monitor sleep apnea, and estimate arterial stiffness. This report provides an analysis of the Internet of Health ecosystem. It explores the technical architectures enabling this shift, the regulatory pathways validating these tools, the economic models sustaining them, and the profound legal and ethical challenges that arise when a consumer device becomes a medical monitor. Defining the Domain: IoT, IoMT and IoH To understand the Internet of Health, one must first delineate it from its technological predecessors. The concept of the Internet of Things (IoT) was coined by Kevin Ashton in 1999 to describe a network of physical objects embedded with sensors and connectivity. In the healthcare context, this evolved into the Internet of Medical Things (IoMT), which traditionally refers to the network of medical devices and applications used in healthcare IT systems. The IoMT is typically characterised by: Institutional Ownership: Devices like MRI machines, infusion pumps, and hospital bed sensors are owned and managed by healthcare providers. Closed Loops: Data often flows within proprietary hospital networks or dedicated servers. High Acuity: The devices support direct clinical interventions, such as robotic surgery assistants or implantable cardioverter-defibrillators (ICDs). In contrast, the Internet of Health (IoH), sometimes referred to as the Internet of Healthy Things (IoHT)—bridges the gap between the consumer and the clinic. It leverages consumer-facing hardware to capture physiological data outside the clinical setting. The IoH is predicated on the "quantified self" maturing into the "medically monitored self," where the smartphone acts as a gateway to transmit vital signs, heart rate variability (HRV), blood oxygen (SpO2), and electrocardiograms (ECG), to providers. Comparative Taxonomy of Connected Health Ecosystems Feature Internet of Things (IoT) Internet of Medical Things (IoMT) Internet of Health (IoH) Primary User General Consumer / Industry Clinicians / Hospitals Patients / Consumers & Clinicians Primary Device Smart Home, Industrial Sensors Infusion Pumps, MRI, Pacemakers Smartwatches, Oura Rings, Withings Scales Data Utility Convenience / Automation Diagnosis / Active Treatment Prevention / Chronic Management / Wellness Regulation FCC / CE (Radio/Safety) FDA Class II/III, MDR Class IIa/IIb/III FDA Class II (De Novo/510k) or General Wellness Data Flow Device -> Cloud -> User App Device -> Hospital Server -> EHR Device -> Cloud -> Middleware -> EHR Connectivity Wi-Fi, Zigbee, Z-Wave Proprietary RF, Wi-Fi, Ethernet Bluetooth (BLE), Cellular, NFC The operational distinction is critical. While IoMT devices are designed for "high-stakes" environments where failure can be fatal (eg. an infusion pump stopping), IoH devices operate in "free-living" environments where data continuity is challenged by user behaviour, motion artifacts and lack of professional supervision.Consequently, the IoH relies on synergistic personal area networks (SPANs), where data from multiple sensors—a watch, a scale, a phone, is synthesised to create a robust physiological profile. The SocioTechnical Drivers of Adoption The rise of the IoH is not merely a product of technological capability but a response to systemic healthcare crises. The Chronic Disease Burden: With the prevalence of chronic conditions like hypertension, diabetes, and heart failure rising, the episodic model of care, where a patient sees a doctor once every few months, is insufficient. The IoH enables continuous remote patient monitoring (RPM), allowing for the detection of deterioration before it necessitates hospitalization. Workforce Shortages: The global shortage of healthcare professionals necessitates tools that can multiply a clinician's reach. By automating the collection of vitals, the IoH reduces the administrative burden on nursing staff and allows physicians to focus on exception management. Consumer Empowerment: Patients are increasingly demanding access to their own health data. The "democratisation of diagnostics" means patients can now track their vascular age or sleep architecture at home, fundamentally altering the doctor-patient power dynamic. The Hardware Revolution: From Gadgets to Medical Instruments The credibility of the Internet of Health hinges on one critical factor: clinical validity. For the IoH to function, the data generated by consumer devices must be accurate enough to inform medical decisions. This section analyses the maturation of key hardware categories, examining the transition from "wellness trackers" to FDA-cleared medical devices. The Smartwatch as a Cardiac Monitor The Apple Watch Series 4, released in 2018, marked a watershed moment in the IoH by incorporating a single-lead electrocardiogram (ECG) capable of detecting atrial fibrillation (AFib). This moved the device from a fitness tracker to a Class II medical device. Clinical Validation and Performance The pivotal Apple Heart Study, conducted in partnership with Stanford Medicine, enrolled over 400,000 participants. The study demonstrated that 34% of individuals who received an irregular pulse notification were subsequently confirmed to have AFib via ECG patch monitoring.10 While this proved the concept, the positive predictive value (PPV) was 0.84, indicating a non-trivial rate of false positives. Subsequent research has refined the understanding of the device's accuracy. A 2024 meta-analysis of 11 studies comprising 4,241 participants found the Apple Watch had a pooled sensitivity of 94.8% and specificity of 95% for detecting AFib compared to a standard 12-lead ECG.3 Another study comparing the watch to 24-hour Holter monitoring in cardiovascular patients found a stark contrast between passive and active monitoring: Passive Irregular Rhythm Notification (IRNF): Low sensitivity (21.4%) but high specificity (100%). This suggests the watch is conservative in generating alerts to avoid alarm fatigue. Active ECG App: When a user actively takes an ECG, the sensitivity rose to 100% and specificity to 99.1%. Google/Fitbit Integration Following Apple's lead, Google's Fitbit has also secured FDA clearance for its PPG-based AFib detection algorithm. The Fitbit Heart Study, which enrolled 455,699 participants, found a PPV of 98% for AFib episodes confirmed by ECG patch monitors The algorithm requires at least 30 minutes of irregular rhythm detection during periods of inactivity to trigger an alert, a design choice specifically intended to minimise motion artifacts and false positives. Samsung Galaxy Watch: Samsung has expanded the clinical utility of the smartwatch even further. In 2024, its Sleep Apnea detection feature received FDA De Novo authorisation, a regulatory first for a consumer smartwatch. The feature uses accelerometer and photoplethysmography (PPG) data to monitor breathing disruptions. Crucially, it is authorised as an over-the-counter (OTC) software-only medical device for adults 22 years and older who have not been previously diagnosed with sleep apnea. This positioning creates a massive funnel for screening undiagnosed populations. The Smart Ring: Sleep Lab on a Finger The smart ring form factor, exemplified by Oura, addresses a key limitation of smartwatches: battery life and comfort during sleep. Validation Status: The Oura Ring uses infrared PPG sensors to track sleep stages (Light, Deep, REM) and HRV. Validation studies against polysomnography (PSG), the gold standard sleep lab test, have shown mixed but improving results. A study by the University of Tokyo on the Gen3 ring found high agreement for total sleep time and sleep efficiency but variable accuracy for sleep staging. Specifically, the ring achieved 90.6% accuracy for REM sleep but only 75.5% for light sleep. Regulatory Strategy: Oura has historically operated in the "general wellness" category to avoid strict FDA oversight.However, the company is pivoting toward medical legitimacy. In late 2024, Oura announced it is pursuing FDA clearance for a blood pressure monitoring feature. Furthermore, Oura partners with the FDA-cleared app Natural Cycles, using the ring’s temperature sensors for fertility tracking. This "component" strategy allows Oura to remain a wellness device while its data powers medical applications. Competitors like the Evie Ring by Movano Health have already achieved FDA clearance for pulse oximetry (SpO2), setting a precedent that the ring form factor can meet clinical standards. The Clinical Scale: Vascular Age and Neuropathy Withings has pioneered the transformation of the humble bathroom scale into a cardiovascular diagnostic tool. Vascular Age and Pulse Wave Velocity (PWV): The Withings Body Cardio and Body Scan scales measure Pulse Wave Velocity (PWV), a metric of arterial stiffness that correlates with cardiovascular health. The device measures the time difference between blood ejection from the heart (detected via ballistocardiography on the scale surface) and the arrival of the pulse in the feet (detected via impedance). Validation: Studies at Georges Pompidou European Hospital have shown a strong correlation between the scale's PWV measurements and gold-standard sphygmometers. Patient Communication: Withings translates this complex hemodynamic data into "Vascular Age," a patient-friendly metric. If a user's vascular age is higher than their chronological age, it indicates arterial stiffness and higher cardiovascular risk. Neuropathy and AFib: The Body Scan scale includes a 6-lead ECG handle. This feature allows the device to detect AFib and also assess sudomotor function (nerve activity) in the feet to screen for diabetic neuropathy. This multi-modal capability effectively brings a peripheral neuropathy exam into the home bathroom. Cuffless Blood Pressure: The Holy Grail Blood pressure monitoring remains the most challenging frontier for wearables. Omron HeartGuide This device is unique as it is a miniaturized oscillometric blood pressure cuff integrated into a watch strap. Validation studies against ambulatory blood pressure monitoring (ABPM) show acceptable accuracy in controlled office settings (mean difference 0.8 mmHg). However, in "free-living" environments, the device significantly underestimated systolic blood pressure by an average of 16 mmHg in some studies. This discrepancy highlights the impact of arm position and motion on accuracy, a persistent challenge for wrist-based BP monitoring. Optical Approaches Other companies are pursuing optical BP monitoring using PPG sensors and machine learning (e.g., analyzing pulse transit time). While Oura and Samsung are exploring this, widespread FDA clearance for calibration-free optical BP monitoring remains elusive due to accuracy concerns.24 The Emergence of the 'Internet of Health' (IoH) The Regulatory Landscape: Navigating the Grey Area The transition from "consumer electronics" to "medical devices" is governed by a complex and shifting regulatory framework. Manufacturers must navigate the "grey area" where intended use definitions determine whether a device is a harmless wellness tracker or a regulated medical instrument subject to strict oversight. The FDA Framework: Intended Use and Risk In the United States, the FDA regulates devices based on intended use. General Wellness Policy Devices that promote a healthy lifestyle without claiming to diagnose, cure, or treat a specific disease are exempt from regulation. A Fitbit that tracks "steps" or "sleep quality" falls under this policy. Medical Device Definition If a wearable claims to "detect atrial fibrillation" or "monitor sleep apnea," it crosses the regulatory line and becomes a medical device. 510(k) Clearance: This pathway is used for devices that are "substantially equivalent" to an existing legally marketed device (predicate). Most wearable ECGs (Apple, Fitbit) use this path. De Novo Pathway: This pathway is for novel low-to-moderate risk devices that have no existing predicate. Samsung’s sleep apnea feature utilised the De Novo track, effectively creating a new classification regulation for consumer sleep apnea screening software. Software as a Medical Device (SaMD) The FDA increasingly regulates the algorithm, not the hardware. This allows the "Samsung Health Monitor App" to be the regulated entity, running on general-purpose hardware (the Galaxy Watch). This decoupling is critical for the IoH, allowing rapid hardware iteration while software undergoes the slower regulatory review process. Cybersecurity Mandates (2023/2025) The Consolidated Appropriations Act of 2023 established mandatory cybersecurity requirements for "cyber devices." The FDA now requires a "Secure Product Development Framework" (SPDF). As of 2025, the FDA has begun issuing warnings and enforcing recalls for medical wearables with cybersecurity vulnerabilities, signalling that data security is now a prerequisite for clinical validity. EU MDR: The Rule 11 Disruption In Europe, the transition from the Medical Device Directive (MDD) to the Medical Device Regulation (MDR)has drastically altered the landscape for health apps and wearables. Rule 11 Up-classification Under the old MDD, many health apps were Class I (low risk) and could self-certify. The MDR’s Rule 11 states that software intended to "provide information which is used to take decisions with diagnosis or therapeutic purposes" is classified as Class IIa or higher. Implication: An app that analyzes heart rate to recommend seeing a doctor (triage/diagnosis support) can no longer be Class I. It requires a Notified Body audit, a Quality Management System (QMS), and robust clinical evaluation reports (CERs). Impact: This has created a bottleneck, forcing many smaller app developers out of the market or pushing them to strip "medical" claims from their products to remain in the unregulated wellness category. UK MHRA: Post-Brexit Agility The UK's Medicines and Healthcare products Regulatory Agency (MHRA) is forging a separate path post-Brexit, aiming to be a pro-innovation regulator for Software as a Medical Device (SaMD). Specific Guidance on Apps: The MHRA has released detailed guidance distinguishing between non-medical apps and medical devices. Symptom Checkers: Software that offers only "reference information" is not a device. However, software that outputs a subset of medical conditions based on user symptoms, or indicates the likelihood of a match, is considered a medical device (Class I or IIa). Adaptive AI: The MHRA is developing frameworks for "adaptive AI", algorithms that learn and evolve over time. Current regulations struggle with algorithms that change after deployment, and the MHRA's "Change Programme" aims to create a regulatory environment that can accommodate this dynamism. The Integration Challenge: Making Data Actionable Even with FDA-cleared hardware and regulatory compliance, the Internet of Health fails if the data cannot reach the clinician in a usable format. This is the interoperability and workflow challenge. Physicians do not have the time to log into separate portals for every patient's device; the data must flow directly into the Electronic Health Record (EHR). The Language of Health: FHIR and SMART The foundational standard enabling the IoH is HL7 FHIR (Fast Healthcare Interoperability Resources). FHIR allows health data to be packaged in discrete, standardised "resources" (e.g., an Observation resource for a heart rate reading) that can be exchanged via APIs. SMART on FHIR This protocol allows third-party applications to launch inside the EHR workflow. Instead of a doctor logging into a separate "Fitbit Dashboard" web portal, a SMART app can appear as a window within the Epic Hyperspace interface, displaying the patient's wearable data alongside their labs and medications. This "single pane of glass" view is essential for adoption. Apple HealthKit Integration Apple leverages FHIR to allow patients to download their health records to their iPhone. Conversely, mechanisms are being built to push HealthKit data (steps, ECGs) back to providers via FHIR APIs. However, this often requires middleware solutions to handle the volume and mapping of data. The Middleware Layer: Validic and Rimidi Direct connections between millions of consumer devices and hospital EHRs are technically chaotic and unmanageable. Middleware platforms have emerged as the translation layer, aggregating disparate data streams into a single clinical pipe. Validic Validic acts as a massive funnel, connecting to over 570 devices (Garmin, Oura, Omron, etc.) and normalising their data streams into a single API. Epic App Orchard Integration: Validic Impact integrates directly into Epic. It enables exception management, clinicians don't see every blood pressure reading; they only get an alert in their Epic InBasket if readings exceed a threshold for a set period. Digital Logbook: This feature allows passive data collection to be written directly into EHR flowsheets, treating home data with the same structural dignity as nurse-collected vitals. Rimidi: Rimidi focuses on specific chronic disease modules (diabetes, heart failure) and visualises data for clinical decision support (CDS). SMART on FHIR: Rimidi lives inside the EHR workflow. It combines PGHD with EHR data (e.g., medication lists) to flag clinical inertia, for example, identifying patients whose glucose levels are consistently high but whose medications have not been adjusted. The Clinician Experience: Avoiding the "Data Tsunami" Research on clinician burnout emphasizes that raw data is a liability, not an asset. Successful IoH implementations use dashboards that perform triage and visualisation. Visualising Trends Clinicians prefer trend lines (sparklines) and summaries over raw numbers. For example, a Glycemic Risk Index simplifies weeks of Continuous Glucose Monitor (CGM) data into a single risk score, allowing a physician to assess control at a glance. Smart Alerting To prevent alert fatigue, systems are moving toward "smart alerts" that require sustained abnormalities to trigger a notification. For instance, the Fitbit AFib algorithm requires at least 30 minutes of irregular rhythm detection to generate an alert, filtering out transient noise that would otherwise overwhelm the clinician. In asthma management studies, nurses reviewed dashboards that only flagged "high-risk" patients based on algorithmically processed peak flow data, ignoring those who were stable. The Economics of Remote Care: Reimbursement and Business Models Technology scales only when it is profitable. The business model of the Internet of Health has shifted from consumer hardware sales to clinical service reimbursement. Governments and insurers are recognizing that paying for remote monitoring is cheaper than paying for hospital readmissions. United States: The CPT Code Ecosystem Medicare (CMS) has established a robust reimbursement framework for Remote Patient Monitoring (RPM)and Remote Therapeutic Monitoring (RTM), turning wearables from a cost center into a revenue generator. Key 2025 CPT Codes & Rates The 2025 Physician Fee Schedule includes specific codes that incentivise the use of these technologies: 99453 (Setup): ~$19.73 (one-time). Reimburses the practice for setting up the device and educating the patient on its use. 99454 (Supply of Device): ~$43.03 (monthly). Reimburses the cost of leasing/supplying the device. Crucially, this requires at least 16 days of data transmission in a 30-day period. 99457 (Management): ~$47.87 (monthly). Reimburses the first 20 minutes of clinical staff time spent communicating with the patient regarding the data. 99458 (Add-on): ~$38.49. For additional 20-minute increments of management time. The "16-Day Rule" Implication The requirement for 16 days of data transmission per month creates a strong economic preference for passive wearables (like watches or rings) over active ones (like cuffs or scales). A smart ring collects data daily without user action, ensuring the 16-day threshold is met automatically and the revenue is secured. An active device relies on the patient remembering to use it, risking non-payment. Germany: The DiGA Model Germany has pioneered the world’s most progressive digital health reimbursement model: the DiGA (Digitale Gesundheitsanwendungen). "App on Prescription" Under the Digital Healthcare Act (DVG), doctors can prescribe health apps listed in the DiGA directory. Statutory health insurers, which cover approximately 90% of the German population, must reimburse these apps. The Fast-Track Mechanism: The DiGA model allows apps to get a "provisional listing" for 12 months. During this period, the manufacturer must conduct a comparative study to prove "positive healthcare effects", either a medical benefit (improved health outcome) or a patient-relevant structural improvement (better adherence, health literacy). This fast-track reduces the barrier to entry, allowing startups to generate revenue while gathering the real-world evidence needed for permanent listing. United Kingdom: Virtual Wards and NHS Tariffs The National Health Service (NHS) is investing heavily in Virtual Wards (Hospital at Home) to relieve bed pressure and manage acute care in the community. Scale and Funding The NHS goal is to deliver 40-50 virtual ward "beds" per 100,000 population. While initial pump-priming funding (£250 million) was provided, systems are now expected to fund virtual wards from core allocations. Cost Effectiveness Evaluations in the NHS South East region showed that virtual wards generated savings exceeding £10 million and avoided over 9,000 hospital admissions. The cost per day on a virtual ward was estimated at ~£187, compared to ~£657 for an acute hospital bed. GP Contract 2025 The 2025/26 GP contract includes specific incentives for "digitally enabled access" and remote monitoring. Practices are required to enable GP Connect functionality, allowing other providers to view relevant records, and to utilise tech-enabled care for risk stratification. Trust, Liability and Ethics: The Human Barrier The final, and perhaps most formidable, barrier to the Internet of Health is human trust and legal safety. The Erosion of Trust Public trust in physicians and hospitals has plummeted from 71.5% in April 2020 to 40.1% in January 2024.This decline creates a paradox: patients distrust the healthcare "system" generally but largely retain trust (85%) in their personal doctor. Physician Trust in Data: Conversely, physician trust in health AI and PGHD is cautiously rising. In 2024, 66% of physicians reported using health AI, a 78% increase from the previous year. However, their primary demand is for "increased oversight" and "liability protection".58 Physicians distrust PGHD not because they oppose data, but because they fear the liability of data they didn't see. The prevailing fear is: "If the data is in the chart, I am responsible for it". Legal Liability and Malpractice The integration of consumer wearables into care creates novel malpractice risks. The "Ostrich Defense" vs. Standard of Care Historically, doctors might avoid looking at wearable data to avoid liability ("if I don't see it, I can't be sued for missing it"). However, legal scholars argue that as AI and wearables become validated, the standard of care will shift. Ignoring a validated alert from an FDA-cleared device could eventually constitute negligence (failure to use available diagnostic tools). Case Law While direct case law on "missed Apple Watch alerts" is sparse, the Masimo v. Apple patent verdict ($634 million) confirmed that Apple Watches function as "patient monitors" in the eyes of the law (specifically patent law).63 This verdict blurs the line between consumer tech and medical equipment, suggesting that courts recognise the medical function of these devices regardless of their marketing. HIPAA & Privacy Consumer devices exist outside HIPAA until the data enters the provider's system. Once integrated (e.g., via Validic into Epic), that data becomes Protected Health Information (PHI). Breaches then expose providers to HIPAA penalties and state-level negligence lawsuits. Ethical Considerations The continuous monitoring of patients raises ethical concerns regarding surveillance and data ownership. Who owns the detailed map of a patient's heart rhythm? Can insurers use this data to deny coverage? While current regulations (like DiGA) prohibit the use of data for disadvantages, the potential for "biometric persecution" remains a concern in the literature. Conclusion: The Convergence The "Internet of Health" has moved beyond the hype phase. The hardware is increasingly clinically valid, with FDA clearances for AFib, sleep apnea, and blood pressure monitoring turning consumer watches into legitimate diagnostic tools. The regulatory pathways, while complex, are clearer than ever before, with the FDA's De Novo track and Germany's DiGA providing roadmaps for market entry. The critical bottleneck is no longer technology; it is workflow integration and economic alignment. Integration: Data must flow silently into the EHR, processed by middleware like Validic or Rimidi that highlights exceptions rather than flooding the inbox with raw noise. Economics: Reimbursement models like CPT codes and NHS virtual ward tariffs must sustain the model, shifting it from a pilot project to a standard operating procedure. The "16-day rule" in the US is already shaping hardware design toward passive monitoring. Trust: Liability shields or clear "standards of care" guidelines must be established to protect physicians who rely on, or reasonably choose to ignore, the deluge of patient-generated data. By 2030, the distinction between a "consumer wearable" and a "medical device" will likely vanish for top-tier devices. The scale on the bathroom floor and the watch on the wrist will be the first line of defense in a healthcare system that is ubiquitous, continuous, and proactive. The Internet of Health is no longer coming; it is here, waiting to be fully integrated. Summary of Key Clinical Validation & Regulatory Milestones (2024/2025) Device / Brand Key Medical Features FDA/Regulatory Status Clinical Validation Highlights Apple Watch ECG (AFib), Irregular Rhythm Notification (IRNF), AFib History FDA Cleared (Class II) for ECG & IRNF. 99.6% specificity for ECG sinus rhythm classification. 94.8% sensitivity for AFib detection vs 12-lead ECG. Oura Ring Sleep Staging, SpO2, Temperature (Fertility), Blood Pressure (In Dev) FDA Cleared for SpO2 (via partnership); BP feature in trials. High accuracy for REM sleep (90.6%) but lower for Light sleep (75.5%) vs PSG. Withings Body Scan 6-Lead ECG, Pulse Wave Velocity (Vascular Age), Neuropathy Screening FDA Cleared for ECG. CE Mark for others. PWV measurements strongly correlated with sphygmometer (gold standard) in hypertensive patients. Samsung Galaxy Watch Sleep Apnea Detection, IHRN, ECG FDA De Novo for Sleep Apnea; FDA Cleared for IHRN/ECG. First FDA-authorised sleep apnea feature for consumer watch. Specificity 100% for IHRN in some trials. Omron HeartGuide Oscillometric Blood Pressure (Wrist Cuff) FDA Cleared (Class II). Validated against ABPM but underestimates SBP by ~16mmHg in free-living conditions due to arm position variance. Fitbit (Google) PPG AFib Detection, ECG FDA Cleared for PPG AFib algorithm & ECG. 98% PPV for AFib episodes in Fitbit Heart Study. Nelson Advisors > MedTech and HealthTech M&A Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital We share our views on the latest Healthcare Technology mergers, acquisitions and partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Founders for Founders > We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide#Divestitures #Corporate #Portfolio #Optimisation #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising#BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Us @ HealthTech events October 2025 Healthcare Summit 2025, London, UK – Chairing the HealthTech M&A Panel Healthcare Summit 2025, London, UK – Chairing the HealthTech Deal Structuring Panel NHS Clinical Entrepreneur Conference, Belfast, Northern Ireland Global Health Exhibition 2025, Riyadh, Saudi Arabia – Chairing the HealthTech M&A Panel November 2025 HealthTech X Summit, London, UK – Chairing the “HealthTech predictions for 2026” Panel MedTech Europe 2025, Valletta, Malta- Speaker on the "Startups, Corporates & Hospitals: How to Build Meaningful MedTech Partnerships" panel MedTech Europe 2025, Valletta, Malta- Judge for the MedTech StartUp Pitch Awards Leaders in Health Summit 2025 December 2025 HealthTech Forward 2025, Barcelona, Spain – Moderating the Health Data Under Attack” Panel Healthcare Club, IESE Business School, Barcelona, Spain HealthInvestor Power List Awards 2025, London, UK – Judging Panel Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk

Left Shift: 2026 NHS IT Market Opportunities Future Health Intelligence Market Insight Webinar https://futurehealthintelligence.com Join Future Health Intelligence for an end of year market insight webinar to review the key changes that have shaped 2025 and to gain insights into the key trends that will drive the NHS and UK health IT market in 2026 and beyond, identifying the key emerging market opportunities from the three left shifts set out in the NHS 10-year Plan: Fit for the Future. We’ll also be examining what are the key trends shaping the wider UK HealthTech sector, with special guest Lloyd Price from Nelson Advisors, one of the UK’s leading HealthTech M&A Advisors joining the webinar to look at key trends that have shaped 2025 and what is expected to be driving the market in 2026. The coming 2026-27 NHS financial year will be first year that significant investment from the £10 billion committed in Spending Review 2025 will begin to land. What market segments are likely to be the beneficiaries from new investment? What are the key timelines of national procurements of new platforms? How will Front Line digitisation evolve in 2026-27 NHS digital maturity trends and emerging opportunities The webinar will also provide attendees with insights on trends from the latest NHS IT budgets and investments, procurement activity trends and predictions for the next 12 months. The webinar will be led by Jon Hoeksma, founder FHI, and Lloyd Price partner at Nelson Advisors. https://futurehealthintelligence.com Nelson Advisors > MedTech and HealthTech M&A Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital We share our views on the latest Healthcare Technology mergers, acquisitions and partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Founders for Founders > We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide#Divestitures #Corporate #Portfolio #Optimisation #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising#BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Us @ HealthTech events October 2025 Healthcare Summit 2025, London, UK – Chairing the HealthTech M&A Panel Healthcare Summit 2025, London, UK – Chairing the HealthTech Deal Structuring Panel NHS Clinical Entrepreneur Conference, Belfast, Northern Ireland Global Health Exhibition 2025, Riyadh, Saudi Arabia – Chairing the HealthTech M&A Panel November 2025 HealthTech X Summit, London, UK – Chairing the “HealthTech predictions for 2026” Panel MedTech Europe 2025, Valletta, Malta- Speaker on the "Startups, Corporates & Hospitals: How to Build Meaningful MedTech Partnerships" panel MedTech Europe 2025, Valletta, Malta- Judge for the MedTech StartUp Pitch Awards Leaders in Health Summit 2025 December 2025 HealthTech Forward 2025, Barcelona, Spain – Moderating the Health Data Under Attack” Panel Healthcare Club, IESE Business School, Barcelona, Spain HealthInvestor Power List Awards 2025, London, UK – Judging Panel Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk

This Week in European HealthTech and MedTech: 28th November 2025 Updates for the week of November 24–28, 2025, are headlined by a major intervention from WHO Europe on AI safety, fresh capital for Nordic oncology innovation, and significant new regulatory guidance from the UK's MHRA. 1. Top Story: WHO Europe's "Fork in the Road" for AI Wednesday, Nov 26 – The World Health Organisation (WHO) Regional Office for Europe released a landmark report on artificial intelligence in healthcare, urging immediate government action. The Warning: The report warns that European healthcare stands at a critical "fork in the road." Without stronger legal safeguards, the rapid deployment of AI tools risks "entrenching inequalities" and compromising patient safety. Key Findings: The review of 50 member states found that while 66% are already using AI for diagnostics (imaging/detection), only 8% (4 countries) have a dedicated national strategic framework for AI in health. Implication: This report is expected to accelerate national-level legislation across the EU to plug these "governance gaps" before the full implementation of the EU AI Act. 2. Investment: Fresh Capital for Nordic Oncology Thursday, Nov 27 – In a week otherwise quiet for "mega-deals," a significant Seed round in Finland highlighted the continued investor appetite for clinical-grade AI. The Deal: Helsinki-based Gosta Labs raised €7.5 million in an oversubscribed Seed round led by deep-tech investor Voima Ventures. The Tech: Unlike general administrative AI, Gosta Labs is building an "AI operating system" specifically for oncology. The platform is designed to handle the extreme complexity of cancer care documentation and decision support, aiming to free up clinician time. Trend: This deal reinforces a key 2025 trend: investors are moving away from generic "health AI" toward highly specialised, vertical-specific solutions that tackle high-burden disease areas like cancer. 3. Regulation: MHRA Updates Digital Mental Health Rules Monday, Nov 24 – The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) issued updated guidance for Digital Mental Health Technologies (DMHTs). New Focus: The updates specifically address "identifying and reporting harms" and "user perspectives." Why it Matters: As prescription digital therapeutics (PDTs) for mental health proliferate, the MHRA is tightening the loop on post-market surveillance. The new guidance clarifies how manufacturers must categorise and report adverse events (e.g., if a chatbot gives unsafe advice or a VR therapy causes physical side effects), signalling a mature regulatory approach to "software as a medical device" (SaMD). 4. Strategic Analysis: The "Digital Omnibus" Reaction While the European Commission's "Digital Omnibus" proposal (aiming to delay high-risk AI rules for medical devices) was unveiled late last week, this week saw the industry formally digest the news. Industry Stance: MedTech Europe officially welcomed the proposal this week but urged policymakers to go further. They are pushing for a "targeted postponement" of MDR re-certification requirements to avoid a bottleneck in 2027/2028, arguing that the AI delay alone solves only half the problem. Market Sentiment: Analysis published this week suggests the "dual burden" of MDR and the AI Act has effectively paused many R&D pipelines, and this proposed delay is now factored into 2026 strategic planning for major European device manufacturers. >>> Updates from the week of November 24–28, 2025, highlight a significant shift in the regulatory landscape for European MedTech, alongside major investment news and post-conference analysis from MEDICA 2025. 1. Top Story: The "AI Act Pause" & Digital Omnibus The most critical strategic development discussed this week is the European Commission's proposal to delay specific "high-risk" AI rules for medical devices. The Proposal: As part of the Digital Omnibus package (officially unveiled Nov 19 but dominating industry strategy this week), the Commission proposed a targeted delay of up to 16 months for the enforcement of high-risk AI obligations. Why it Matters: MedTech associations have fiercely lobbied for this, citing the "dual burden" of complying with both the Medical Device Regulation (MDR) and the new AI Act. This delay is designed to give manufacturers breathing room to align technical standards without stalling innovation or market access. Impact: This week, industry analysis has focused on how this "pause" will allow companies to re-evaluate their R&D timelines for AI-driven diagnostic and surgical tools for 2026. 2. Investment: Major Capital for European Innovation Despite a generally tight funding environment, a massive capital injection has signaled renewed investor confidence in the sector. Sofinnova Partners Closures Fund XI: Paris-based VC firm Sofinnova Partners finalized its "Capital XI" fund at €650 million. Focus: The fund is specifically targeted at early-stage HealthTech and MedTech companies (along with biotech). Significance: This is one of the largest early-stage healthcare funds in Europe recently, offering a critical lifeline to startups facing the "Series A crunch" and aiming to keep deep-tech innovation within Europe. Regional Funding: Finnish startup Gosta Labs raised €7.5 million this week to advance its AI-driven oncology platform, highlighting the continued investor appetite for AI solutions that improve clinical workflow efficiency. 3. Regulatory & Product Approvals EC Approves First Non-CF Bronchiectasis Treatment: The European Commission granted marketing authorisation for Brinsupri (brensocatib). This is the first approved treatment in the EU for non-cystic fibrosis bronchiectasis, marking a major milestone for patients with this chronic lung condition. UK MHRA Updates: The UK regulator (MHRA) issued new guidance this week on digital mental health technologies, securing £2 million in funding (jointly with NICE) to develop clearer regulatory pathways for these tools. 4. Market Moves & Innovation (Post-MEDICA) Following the conclusion of MEDICA 2025 in Düsseldorf (Nov 17–20), this week has been defined by the industry "digesting" key announcements: European Robotics Challenger: Industry talk has centered on Amplitude Surgical (a subsidiary of Zydus Lifesciences), which recently received the CE Mark for its "Andy" orthopaedic robotic system. This positions a verified European competitor against established US players (like Stryker or Zimmer Biomet) in the knee and hip surgery market. Hospital 4.0 Focus: A key theme emerging from the conference reviews this week is "Hospital 4.0"—specifically the shift from hardware-focused purchasing to software-integrated ecosystems that connect patient monitoring, diagnostics, and electronic health records. Nelson Advisors > MedTech and HealthTech M&A Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital We share our views on the latest Healthcare Technology mergers, acquisitions and partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Founders for Founders > We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide#Divestitures #Corporate #Portfolio #Optimisation #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising#BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Us @ HealthTech events October 2025 Healthcare Summit 2025, London, UK – Chairing the HealthTech M&A Panel Healthcare Summit 2025, London, UK – Chairing the HealthTech Deal Structuring Panel NHS Clinical Entrepreneur Conference, Belfast, Northern Ireland Global Health Exhibition 2025, Riyadh, Saudi Arabia – Chairing the HealthTech M&A Panel November 2025 HealthTech X Summit, London, UK – Chairing the “HealthTech predictions for 2026” Panel MedTech Europe 2025, Valletta, Malta- Speaker on the "Startups, Corporates & Hospitals: How to Build Meaningful MedTech Partnerships" panel MedTech Europe 2025, Valletta, Malta- Judge for the MedTech StartUp Pitch Awards Leaders in Health Summit 2025 December 2025 HealthTech Forward 2025, Barcelona, Spain – Moderating the Health Data Under Attack” Panel Healthcare Club, IESE Business School, Barcelona, Spain HealthInvestor Power List Awards 2025, London, UK – Judging Panel Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk

Who are the leading M&A Advisors for European HealthTech and MedTech Founders? The Strategic Landscape of European HealthTech and MedTech M&A Advisory: 2024-2025 Comprehensive Report The architecture of Mergers and Acquisitions (M&A) advisory within the European HealthTech and MedTech sectors has undergone a radical structural transformation throughout the fiscal periods of 2024 and 2025. The market, previously viewed as a continuum of deal sizes, has fractured into distinct ecosystems defined not merely by transaction volume, but by the specific "technological lineage" of the asset in question. This report posits that the selection of an M&A advisor is no longer a function of prestige alone, but of strategic alignment with one of two diverging paradigms: the "Industrial MedTech" track and the "Digital Health" track. For the European founder, the implications of this bifurcation are profound. The convergence of traditional medical technology, exemplified by hardware, implants and diagnostics, with high-velocity digital capabilities has created a hybrid asset class often termed "Connected Care" or "TechBio." This convergence has rendered purely financial advisory insufficient. The leading advisors of 2025 and 2026 are those who possess not only the balance sheet to underwrite multi-billion dollar transactions but the technical fluency to articulate the value of AI-driven diagnostics, remote patient monitoring (RPM) stacks and interoperable data platforms to a cautious, diligence heavy buyer universe. The empirical data gathered for this analysis indicates a clear hierarchy. At the apex of deal value, global powerhouses like Goldman Sachs and J.P. Morgan continue to dominate, particularly in handling large-cap corporate carve-outs and multi-billion dollar exits such as the sale of Shockwave Medical or the Olink acquisition. However, in terms of volume and relevance to the mid-market founder, the demographic most prevalent in the European innovation ecosystem, firms like Rothschild & Co, Houlihan Lokey and highly specialised boutiques like Nelson Advisors, Arma Partners and Clipperton have emerged as the primary engines of liquidity. Furthermore, 2024 has witnessed the solidification of the "Transatlantic Bridge." With United States capital markets and strategic acquirers remaining the primary source of liquidity for European assets, the strategic acquisition of Bryan, Garnier & Co by Stifel Financial Corp represents a watershed moment. It signals a definitive market consolidation where European advisors must possess integrated US distribution capabilities to remain competitive. This report provides an exhaustive dissection of these trends, offering a granular view of the advisors, the deal mechanics and the strategic imperatives driving the European HealthTech M&A market. It synthesises data from over 200 distinct data points to construct a definitive guide for founders, boards and investors navigating the exit environments of 2025 and 2026. The Macro-Strategic Environment: Drivers of Valuation and Activity To accurately assess the positioning of the leading M&A advisors, one must first contextualize the macroeconomic and sector-specific environment in which they operate. The period of 2024-2025 is characterised by a "Selective Recovery" in M&A activity. Following the post-COVID volatility and the interest rate shocks of 2022-2023, the market has stabilised, but the criteria for capital deployment have fundamentally tightened. The Shift from "Growth at All Costs" to "Unit Economics" The era of unrestricted capital flow has been definitively replaced by a focus on unit economics, EBITDA positivity, and platform scalability. Advisors are now tasked with positioning HealthTech assets not merely as high-growth software companies but as essential infrastructure components that offer immediate operational efficiencies to healthcare systems. The leading advisors identified in this report have adapted their equity stories to emphasise three core pillars: Operational Efficiency: How the target asset reduces costs for hospitals or payers. For instance, platforms like Caresyntax are valued not just on SaaS metrics but on their ability to improve operating room throughput. Regulatory Moats: The value of CE MDR (Medical Device Regulation) certification and FDA clearance as defensible assets. AI Integration: Moving beyond the hype to demonstrate clinical utility and reimbursement pathways for Artificial Intelligence applications. The Regulatory Arbitrage: EU AI Act and EHDS A critical differentiator for top-tier advisors in 2025 is their ability to navigate the complex regulatory landscape of the European Union. The introduction of the EU AI Act in August 2024 and the forthcoming implementation of the European Health Data Space (EHDS) in 2025 have fundamentally altered due diligence processes. Advisors who have integrated regulatory expertise into their M&A practice are gaining market share. The EU AI Act categorises medical AI as "high-risk," imposing stringent compliance obligations. Consequently, boutique advisors like Nelson Advisors and legal partners like Latham & Watkins are leveraging compliance as a valuation driver, arguing that a fully compliant AI stack commands a premium due to the "de-risking" it offers the acquirer. This effectively turns a regulatory burden into a competitive moat for the seller. The Private Equity "Roll-Up" Engine Private Equity (PE) remains the dominant force in European HealthTech M&A, driving volume through "buy-and-build" strategies. The market has seen a surge in secondary buyouts and platform augmentations, where a PE-backed platform acquires smaller, innovative players to expand geographic reach or technological capability. This trend heavily favors advisors with deep, legacy relationships in the PE community. Firms like Rothschild & Co and Houlihan Lokey excel at this "matchmaking" between founders and financial sponsors. The data confirms that PE deal volume in European healthcare reached record highs in 2024, exceeding previous peaks. This necessitates an advisor who understands the specific financial engineering requirements of sponsors, such as debt-service coverage ratios and recurring revenue stability. Market Activity Overview: The League Table of Influence The following table summarises the key market activity metrics for the leading advisors in the European healthcare sector for 2024, highlighting the dominance of specific firms in value versus volume. Advisor Primary Metric (2024) Key Strength Notable Deal Involvement Goldman Sachs #1 by Value ($97.5bn+) Large-cap exits, Carve-outs, IPOs Olink, Zeus Health, Shockwave Rothschild & Co #1 by Volume (132 deals) Mid-market ubiquity, PE relationships ELITechGroup, Broad mid-market J.P. Morgan Top Tier Value Complex cross-border M&A Olink, Shockwave, Enovis/Lima Houlihan Lokey High Volume Healthcare services, MedTech Bryan Garnier (Sell-side advisor) Arma Partners Digital Specialist Digital Health, SaaS, Deep Tech Lasso, Project 58bn Deal Value Jefferies Sector Specialist Pharma services, Diagnostics ELITechGroup (Advisor to PAI) Nelson Advisors Boutique Specialist Founder led exits, Digital Health, HealthTech, MedTech Strategic mid market HealthTech Clipperton Tech Specialist High-growth Tech/SaaS Hublo, DentalMonitoring Kempen & Co Life Science Specialist Biotech, Diagnostics, Benelux Galecto, Curevac, Hansa The Bulge Bracket Hegemony: Architects of the Mega-Exit For European founders who have achieved "Unicorn" status or are involved in multi-billion dollar corporate carve-outs, the Bulge Bracket banks remain indispensable. Their value proposition lies in their balance sheet capacity, global distribution networks, and ability to manage the intense regulatory scrutiny associated with mega-deals. Goldman Sachs: The Prestige Leader Goldman Sachs retains its position as the preeminent financial advisor by deal value in Europe. In 2024, the firm advised on approximately $417.8 Billion worth of deals across sectors, with a dominant showing in healthcare. Strategic Positioning: Goldman Sachs focuses on "big-ticket" transactions. They are the advisor of choice for large corporate separations and sales to major US strategic acquirers. Their involvement signals to the market that an asset is a premium, "must-have" property. Their capacity to mobilise their Asset Management and Private Credit divisions to finance the very deals they advise on creates a self-reinforcing cycle of dominance. Key Transactional Case Studies: Olink Holding ($3.1 Bn): Goldman Sachs acted as a financial advisor to Olink in its acquisition by Thermo Fisher Scientific. This deal exemplifies Goldman's strength in cross-border diagnostics deals, navigating the sale of a Swedish-based asset to a US giant. The deal required navigating complex Swedish takeover rules alongside US securities law. Zeus Health ($3.4 Bn Enterprise Value estimated): Advised Zeus, a manufacturer of polymer components for medical procedures, on its sale to EQT Private Equity. This transaction highlights their capability in the MedTech supply chain and industrial healthcare segments. Crucially, the Private Credit business within Goldman Sachs Asset Management served as the lead lender, demonstrating the integrated "one-firm" approach. Sanofi Consumer Health: Mandated (alongside Morgan Stanley) to handle the potential separation of Sanofi’s consumer health unit, a deal of massive complexity valued potentially at €20 Billion. J.P. Morgan: The Cross-Border Heavyweight J.P. Morgan (JPM) consistently ranks alongside Goldman Sachs, often acting as the lead advisor on the largest and most complex transactions. Their healthcare practice is renowned for its depth in life sciences and MedTech, particularly in bridging European innovation with US capital. Strategic Positioning: JPM excels in complex, cross-border public-to-private transactions and mergers involving listed entities. Their reach into the US boardroom is unparalleled, making them essential for European companies seeking US acquirers. Key Transactional Case Studies: Shockwave Medical ($13.1Bn): J.P. Morgan served as the exclusive financial advisor to Johnson & Johnson in its acquisition of Shockwave Medical. While Shockwave is US-based, the deal has significant implications for the European cardiovascular market and highlights JPM's dominance in the MedTech innovation exit landscape. Olink Holding: Served as the lead financial advisor to Olink, working alongside Goldman Sachs. The dual mandate of JPM and Goldman on a single deal underscores the necessity of top-tier banking support for multi-billion dollar valuations. Enovis / LimaCorporate: JPM acted as a financial advisor to Enovis in its acquisition of Italian orthopaedic leader LimaCorporate. This demonstrates their capability in facilitating US corporates acquiring European legacy MedTech assets. Morgan Stanley: The Strategic Architect Morgan Stanley maintains a strong position in the top tier, often advising on deals that involve significant strategic transformation or complex equity structures. Strategic Positioning: The firm is heavily involved in advising financial sponsors and large corporates on portfolio optimisation. Their reputation is built on long-term relationship banking with the largest healthcare conglomerates. Key Transactional Case Studies: LimaCorporate: Advised the seller, EQT Private Equity, on the disposal of LimaCorporate to Enovis. This highlights Morgan Stanley's strong relationship with top-tier Private Equity firms looking to exit comprehensive European assets. Sanofi Carve-out: Selected as one of the key advisors for the Sanofi consumer health separation, reinforcing their status as a go-to bank for massive corporate restructurings. The Mid-Market Engine Room: Volume, Reach and Depth While the Bulge Bracket firms capture the headlines with mega-deals, the "engine room" of the European HealthTech M&A market is occupied by firms that combine global reach with intense local coverage. These firms typically lead in deal volume, advising on the hundreds of €50m–€1bn transactions that constitute the bulk of the market. Rothschild & Co: The Ubiquitous Market Leader Rothschild & Co stands apart as the most active M&A advisor in Europe by volume. Their model is unique: a deeply entrenched network of local offices across France, Germany, the UK, and the Benelux allows them to cover the "Mittelstand" and family-owned businesses as effectively as large corporates. Strategic Focus & Culture: Rothschild dominates the mid-market. They are the default choice for European founders selling businesses in the €100m–€1bn range. Their "Global Advisory" division is structured to provide independent advice, unencumbered by the balance sheet conflicts that can sometimes affect the Bulge Bracket banks. They are particularly adept at navigating the "softer" issues of family ownership and succession. Key Transactions: ELITechGroup: Rothschild acted as a key advisor to PAI Partners (the seller) in the sale to Bruker. This reflects their long-standing relationship with the French private equity ecosystem, where they often serve as the "House Bank" for sponsors like PAI. General Mid-Market: They are consistently ranked #1 by volume, advising on 296 deals (across all sectors, but heavily weighted to healthcare) in 2024. Houlihan Lokey: The Challenger Houlihan Lokey has expanded its European footprint, challenging Rothschild for the volume crown. Known historically for restructuring, their Corporate Finance practice is now a juggernaut in the mid-market. Strategic Focus: Houlihan Lokey is noted for its dedicated healthcare teams that operate with a high degree of sector specialisation. They are particularly strong in selling to financial sponsors (PE), leveraging a data-driven approach to buyer mapping. Strategic Significance: Advising Bryan Garnier: Houlihan Lokey acted as the sell-side advisor to Bryan, Garnier & Co in its sale to Stifel. This is a significant meta-transaction, demonstrating that when investment banks themselves need to sell, they turn to Houlihan Lokey for execution. Jefferies: The Healthcare Pure-Play Jefferies has carved out a distinct niche as a "pure-play" investment bank with a healthcare practice that rivals the Bulge Bracket in terms of depth and expertise. Strategic Focus & Ecosystem: Jefferies is renowned for its aggressive and highly specialized healthcare team. A key differentiator is their London Healthcare Conference, the largest healthcare-dedicated conference in Europe. This event serves as a primary deal-making venue, giving Jefferies a unique convening power that competitors lack.30 Key Transactions: ELITechGroup: Jefferies was understood to be advising PAI Partners on the sale of ELITechGroup to Bruker, a deal valued at €870 million ($942 million). This transaction underscores their capability in managing exits for major European private equity firms to US strategic buyers. First Advantage / Sterling Check: Involved in this $2.2bn deal, demonstrating their capacity for larger transaction sizes. The Digital & Specialist Boutiques: "Founders for Founders" For the founder of a digital health startup, an AI-radiology platform, or a SaaS-based clinic management system, the Bulge Bracket banks may lack the specific technological fluency required to maximize valuation. This gap is filled by specialised boutique firms that position themselves as domain experts. Nelson Advisors: The "Founders for Founders" Specialist https://nelsonadvisors.co.uk Nelson Advisors has established a reputation as a high-touch, sector-exclusive firm focused on the lower-to-middle market ($25m - $250m). Unique Value Proposition: Unlike traditional banks staffed by career financiers, Nelson Advisors is led by former founders who have successfully exited HealthTech businesses. This "DNA" allows them to empathise with the founder's journey and better articulate the technical nuance of the asset. They focus exclusively on Healthcare Technology (Digital Health, Health IT, AI) and do not dilute their focus with generalist MedTech or Pharma. Key Leadership: Lloyd Price: Co-Founder and Partner. A serial entrepreneur who exited Zesty to Induction Healthcare Group. He brings deep operational credibility. Paul Hemings: Co-Founder and Partner. Combines investment banking background with entrepreneurial exits. https://nelsonadvisors.co.uk GP Bullhound: The Transatlantic Tech Bank GP Bullhound operates as a technology investment bank with a strong focus on software and digital services. They are particularly active in cross-border deals involving US buyers. Key Transactions: Flo Health: Acted as exclusive financial advisor to Flo Health on its $200m Series C investment from General Atlantic, valuing the company at over $1 billion. This is a landmark deal for the "FemTech" and B2C digital health sector. Ottonova: Advised the German digital health insurer on its fundraising, demonstrating their capability in the InsurTech intersection. Torch Partners: The Deep Tech & Software Advisor Torch Partners is a London-based boutique known for handling complex software and data-rich assets. Strategic Focus: They advise on M&A and Private Capital Markets for companies in the Enterprise SaaS, Data, and Tech-enabled services sectors. They are increasingly active in "Deep Tech" healthcare applications such as quantum computing for drug discovery. Key Transactions: Oxford Ionics: Participated in the £30m Series A funding. While this is a quantum computing company, its applications in life sciences (drug discovery simulation) place it firmly in the HealthTech deep-tech bucket. Regional Champions: The Power of Local Networks The European market is not monolithic; advisor strength varies significantly by geography. Founders must consider whether a "Pan-European" approach or a "Local Champion" approach is best for their specific exit. Benelux & Life Sciences: Kempen & Co (Van Lanschot Kempen) Kempen is a powerhouse in the Life Sciences and Healthcare sector, particularly for Biotech and MedTech companies in the Benelux region. Strategic Focus: They excel in Equity Capital Markets (ECM) and M&A for life sciences. They are the go-to bank for IPOs on Euronext Amsterdam or Brussels. Key Transactions: Advised on the IPOs and capital raises for Galecto, Curevac, and Hansa Biopharma. Leadership: Jan de Kerpel is the Head of Life Sciences & Healthcare and is a renowned figure in the sector. The Franco-German Axis: Oddo BHF Oddo BHF is a unique financial institution that operates as a binational (French and German) bank. Strategic Expansion: In 2025, they significantly strengthened their corporate finance platform with the appointments of Hervé Ronin (Group Head of Healthcare) and Paul de Mestier (Head of Healthcare France) Partnership: They have deepened a partnership with Raiffeisen Bank International (RBI) to cover the DACH and CEE (Central and Eastern Europe) regions, creating a massive coverage network for mid-market healthcare deals. DACH Region: Goetzpartners Based in Munich, Goetzpartners is a leading advisory firm for the "Mittelstand." Strategic Focus: They combine M&A advisory with management consulting, offering a "Strategy-first" approach to exits. Key Transactions: Advised Merck KGaA on the sale of Allergopharma and the sale of AbisDu Pflege(Care services). 6.4 USA-Europe Consolidation: Stifel & Raymond James A major trend is the acquisition of European boutiques by US firms to capture cross-border flow. Stifel / Bryan Garnier: Stifel's acquisition of Bryan, Garnier & Co is the most significant consolidation event of the year. It gives Stifel a massive European footprint in healthcare and technology, while offering Bryan Garnier's clients seamless access to US capital markets. Raymond James: Has expanded its European healthcare investment banking practice with senior hires, focusing on the middle market and competing directly with firms like William Blair and Baird. Conclusion and Strategic Outlook (2025-2026) The M&A advisory landscape for European HealthTech and MedTech founders is settling into a clearly defined structure. For the "Unicorn" Founder (>€1bn Valuation) The choice remains firmly with the Bulge Bracket (Goldman Sachs, J.P. Morgan, Morgan Stanley). Their ability to deliver US buyers and manage complex cross-border regulatory frameworks is unmatched. For the Mid-Market Founder (€50m - €500m): This is the most competitive and dynamic segment. Rothschild & Co is the safe, ubiquitous choice with deep networks. However, Houlihan Lokey and Jefferies offer alternatives with strong US ties. For the Digital Health/MedTech/HealthTech Founder: Boutiques are winning by selling "expertise" rather than "scale." Nelson Advisors, Arma Partners and GP Bullhound are the preferred partners for founders who need an advisor that understands the difference between a medical device and a SaaS platform. Emerging Trends to Watch: Regulatory Valuation: Advisors who can quantify the value of AI compliance (EU AI Act) will win mandates. Transatlantic Consolidation: Expect more acquisitions of European boutiques by US mid-market banks (following the Stifel/Bryan Garnier model) to secure deal flow. The "Product DD" Standard: Technical due diligence (Code & Co) will become a standard pre-requisite for M&A, not just an afterthought, as software becomes the core value driver of MedTech assets. In summary, the "leading" advisor is no longer a static title but a function of the specific asset class (Hardware vs. Software), the target valuation (Mega vs. Mid-Cap) and the desired exit destination (US Strategic vs. European PE). Founders must align their choice of advisor with these strategic realities to maximize liquidity in the evolving 2025 marketplace. Nelson Advisors > MedTech and HealthTech M&A Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital We share our views on the latest Healthcare Technology mergers, acquisitions and partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Founders for Founders > We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide#Divestitures #Corporate #Portfolio #Optimisation #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising#BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Us @ HealthTech events October 2025 Healthcare Summit 2025, London, UK – Chairing the HealthTech M&A Panel Healthcare Summit 2025, London, UK – Chairing the HealthTech Deal Structuring Panel NHS Clinical Entrepreneur Conference, Belfast, Northern Ireland Global Health Exhibition 2025, Riyadh, Saudi Arabia – Chairing the HealthTech M&A Panel November 2025 HealthTech X Summit, London, UK – Chairing the “HealthTech predictions for 2026” Panel MedTech Europe 2025, Valletta, Malta- Speaker on the "Startups, Corporates & Hospitals: How to Build Meaningful MedTech Partnerships" panel MedTech Europe 2025, Valletta, Malta- Judge for the MedTech StartUp Pitch Awards Leaders in Health Summit 2025 December 2025 HealthTech Forward 2025, Barcelona, Spain – Moderating the Health Data Under Attack” Panel Healthcare Club, IESE Business School, Barcelona, Spain HealthInvestor Power List Awards 2025, London, UK – Judging Panel Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk